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Abstract The Rotterdam Study is a prospective cohort
study ongoing since 1990 in the city of Rotterdam in The
Netherlands. The study targets cardiovascular, endocrine,
hepatic, neurological, ophthalmic, psychiatric, dermato-
logical, otolaryngological, locomotor, and respiratory dis-
eases. As of 2008, 14,926 subjects aged 45 years or over
comprise the Rotterdam Study cohort. Since 2016, the
cohort is being expanded by persons aged 40 years and
over. The findings of the Rotterdam Study have been pre-
sented in over 1500 research articles and reports (see www.
erasmus-epidemiology.nl/rotterdamstudy). This article
gives the rationale of the study and its design. It also
presents a summary of the major findings and an update of
the objectives and methods.
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Introduction
The Rotterdam Study was designed in the mid-1980s as a
response to the demographic changes that were leading to
an increase of the proportion of elderly people in most
populations [1]. It was clear that this would produce a
strong rise in elderly people living with diseases, as most
diseases cluster at the end of life, and that to discover the
causes of diseases in the elderly one would have to study
risk factors of those diseases [2]. A major approach to
finding causes is the prospective follow-up study, which
has proven quite effective in finding causes of heart disease
and cancer.
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The design of the Rotterdam Study
The design of the Rotterdam Study is that of a prospective
cohort study among, initially, 7983 persons living in the
well-defined Ommoord district in the city of Rotterdam in
The Netherlands (78% of 10,215 invitees). They were all
55 years of age or over and the oldest participant at the
start was 106 years [3]. The study started with a pilot phase
in the second half of 1989. From January 1990 onwards
participants were recruited for the Rotterdam Study. Fig-
ure 1 gives a diagram of the various cycles in the study. In
2000, 3011 participants (out of 4472 invitees) who had
become 55 years of age or moved into the study district
since the start of the study were added to the cohort. In
2006 a further extension of the cohort was initiated in
which 3932 subjects were included, aged 45–54 years, out
of 6057 invited, living in the Ommoord district. By the end
of 2008, the Rotterdam Study therefore comprised 14,926
subjects aged 45 years or over [4, 5]. The overall response
figure for all three cycles at baseline was 72.0% (14,926 of
20,744). Since summer of 2016, another extension has
started that includes all participants aged 40 years and
over. The recruitment of this extension is expected to be
completed in 2019 and yield around 4000 new participants.
The participants were all examined in some detail at
baseline. They were interviewed at home (2 h) and then
had an extensive set of examinations (a total of 5 h) in a
specially built research facility in the centre of the district.
These examinations focused on possible causes of invali-
dating diseases in the elderly in a clinically state-of-the-art
manner, as far as the circumstances allowed. The emphasis
was put on imaging (of heart, blood vessels, eyes, skeleton
and later brain) and on collecting biospecimens that
enabled further in-depth molecular and genetic analyses.
These examinations were repeated every 3–4 years in
characteristics that could change over time. There were
examination cycles from 1990 to 1993, from 1993 to 1995,
from 1997 to 1999, from 2000 to 2001, from 2002 to 2004,
from 2004 to 2005, from 2006 to 2008, from 2009 to 2011,
from 2011 to 2012, from 2012 to 2014, from 2014 to 2015,
and from 2015 onwards (Fig. 1). In spring 2016, the fourth
examination cycle for the second cohort (RS-II-4) was
finished. In summer 2016 a fourth cohort was established.
The age range for this new cohort is predominantly
40–55 years, the anticipated number of participants is
4000.
The participants in the Rotterdam Study are followed for
a variety of diseases that are frequent in the elderly:
coronary heart disease, heart failure and stroke, Parkinson
disease, Alzheimer disease and other dementias, depression
and anxiety disorders, macular degeneration and glaucoma,
COPD, emphysema, liver diseases, diabetes mellitus,
osteoporosis, dermatological diseases and cancer.
Fig. 1 Diagram of examination cycles of the Rotterdam Study (RS).
RS-I-1 refers to the baseline examination of the original cohort (pilot
phase 07/1989–12/1989; cohort recruitment 01/1990–09/1993). RS-I-
2, RS-I-3, RS-I-4, RS-I-5, and RS-I-6 refer to re-examinations of the
original cohort members. RS-II-1 refers to the extension of the cohort
with persons from the study district that had become 55 years since
the start of the study or those of 55 years or over that migrated into
the study district. RS-II-2, RS-II-3, and RS-II-4 refer to re-examina-
tions of the extension cohort. RS-III-1 refers to the baseline
examination of all persons aged 45 years and over living in the
study district that had not been examined already (i.e., mainly
comprising those aged 45–60 years). RS-III-2 refers to the first re-
examination of this third cohort. Examination RS-I-4 and RS-II-2
were conducted as one project and feature an identical research
program. Similarly, examinations RS-I-5, RS-II-3, and RS-III-2 share
the same program items. Also, examinations RS-I-6 and RS-II-4 are
conducted as one project. RS-IV-1 refers to the baseline visit of a new
cohort, established in summer 2016
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The Rotterdam Study has been approved by the insti-
tutional review board (Medical Ethics Committee) of the
Erasmus Medical Center and by the review board of The
Netherlands Ministry of Health, Welfare and Sports. The
approval has been renewed every 5 years, as well as with
the introduction of major new elements in the study (e.g.,
MRI investigations).
In the remainder of this article the objectives and major
findings will be presented with an update of the research
methods for cardiovascular diseases, dermatological dis-
eases, endocrine diseases, liver diseases, neurological dis-
eases, ophthalmic diseases, psychiatric diseases,
respiratory diseases, as well as for genetic and biomarker
studies and for pharmaco-epidemiologic studies. The
emphasis is on major findings from the preceding 2 years
(since the previous update paper [6].
For relevant recent EJE references see [6–24].
Cardiovascular diseases
Objectives
Research on the epidemiology of cardiovascular disease
focuses on the etiology, prediction, and prognosis of car-
diovascular disorders (including coronary heart disease,
stroke, and heart failure), type 2 diabetes (T2D) and
metabolic syndrome. The main emphasis is on prevention
and management of a first cardiovascular event but pre-
vention of secondary events is also an area of interest.
Putative risk factors include five groups: lifestyle factors,
endocrine factors, factors involved in hemostasis, inflam-
mation and endothelial function, metabolomic factors and
genetic factors. We have five specific focused themes:
1. Lifestyle focused on evaluating the role of lifestyle
factors (including nutrition, physical activity, sleep and
smoking) in maintaining cardiovascular health as well
as the interactions that lifestyle factors might have on
other factors (e.g. genes, epigenetic marks and
medications).
2. Biomarkers and genes aimed to identify relevant
biomarkers for the identification of novel mechanisms
of disease. These incorporate both molecular and
genetic factors together with their potential interactions.
Genomics, epigenetic marks and metabolomics play a
key role.
3. Prediction and women’s cardiovascular health aimed to
improve the identification of individuals at increased
risk of developing cardiovascular disease in order to
point out windows of opportunities that could permit
early preventive interventions and personalised care. A
special focus is given to evaluating specific factors and
formulating targeted strategies to prevent cardiovascular
disease in women.
4. High risk focused on predictors and prognosis of
chronic cardiovascular conditions, like heart failure,
pulmonary hypertension, and atrial fibrillation.
5. Imaging this work theme aims to identify the contribu-
tion that new technologies can provide to the maximum
benefit of early diagnosis and accurate prognosis. Major
focus is on non-invasive assessment of atherosclerosis
to improve the understanding of the atherosclerotic
process and the prediction of cardiovascular disease,
including measurement of coronary calcification with
electron-beam and multi-detector CT (MDCT) and
carotid plaque characterization by MRI.
Major findings
Anthropometrics and cardiovascular disease
We evaluated different anthropometric measures, including
body mass index, waist circumference, waist to height
ratio, waist to hip ratio and a body shape index in associ-
ation with all-cause, cardiovascular and cancer mortality.
We have shown that among different anthropometric
measures, a body shape index (ABSI) was strongly asso-
ciated with the risk of all-cause, cardiovascular and cancer
mortality [25]. In contrast to body mass index (BMI) and
waist circumference (WC), ABSI showed a differential
association with fat mass and fat-free mass in men, but not
in women. This could suggest ABSI as a useful tool for
identifying men at higher risk of sarcopenic obesity [26].
While the role of BMI for prediction of CVD among the
elderly remains controversial, we found that the presence
of obesity without metabolic syndrome did not confer a
higher CVD risk in the Rotterdam Study. However,
metabolic syndrome was strongly associated with CVD
risk, and was associated with an increased risk in all BMI
categories [27]. We also observed that while obesity had no
effect on total life expectancy in older individuals of the
Rotterdam Study, it increased the risk of having CVD
earlier in life and consequently extended the number of
years lived with CVD [28]. Furthermore, among individ-
uals who developed CVD during follow-up in the Rotter-
dam Study, we identified 3 distinct BMI trajectories. These
trajectories marked 3 distinct groups of ‘‘stable weight’’,
‘‘progressive weight gain’’, and ‘‘progressive weight loss’’
during follow-up. Other cardiovascular risk factors
including glucose and lipid levels differed between the
identified BMI subgroups, further highlighting that CVD is
a heterogeneous disease with different pathophysiological
pathways [27]. Within the European Network for Genetic
and Genomic Epidemiology (ENGAGE) consortium, using
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a mendelian randomization approach, we found that adi-
posity, as indicated by body mass index, has a causal
relationship with coronary heart disease, heart failure and
for the first time, ischemic stroke [29]. Also, there were
age- and sex-specific causal effects of adiposity on car-
diovascular risk factors, including cholesterol, blood pres-
sure, fasting levels of insulin and C-reactive protein [30].
Comparison of guidelines
The new American College of Cardiology/American Heart
Association (ACC/AHA) guidelines introduced a new
cardiovascular (CVD) prediction model and lowered the
threshold for treatment with statins to a 7.5% 10-year hard
atherosclerotic cardiovascular disease (ASCVD) risk.
Using 4854 asymptomatic participants from the popula-
tion-based Rotterdam Study, we determined the implica-
tions of the new ACC/AHA guideline’s treatment threshold
and risk prediction model and compared it with the Adult
Treatment Panel III (ATP-III), and the European Society of
Cardiology (ESC) guidelines. We showed that proportions
of individuals eligible for treatment with statins differed
substantially among the 3 guidelines [31]. The ACC/AHA
guideline would recommend statins for nearly all men and
two-thirds of women, proportions exceeding those with the
ATP-III or ESC guidelines. All risk prediction models
underlying the 3 guidelines provided poor calibration and
moderate to good discrimination in our population. To
facilitate better clinical decision making, improving risk
predictions and setting appropriate population-wide
thresholds are necessary.
Women’s health
Women experience multiple health issues throughout their
life course differently from men. Therefore, attention to
women’s health is important in all stages in life. To
improve women’s quality of life and guarantee a long-
lasting and active role for women in society, prevention of
chronic diseases and disability is a key aspect. Our focus,
therefore, in the women’s health group is on the major
health issues for peri- and post-menopausal women, their
risk factors, and prevention strategies [32].
As menopausal health is a crucial aspect in healthy and
successful aging, we aimed to characterize a concept for
healthy menopause. We conceptualized healthy menopause
as a dynamic state, following the permanent loss of ovarian
function, which is characterized by self-perceived satis-
factory physical, psychological and social functioning,
incorporating disease and disability, allowing the attain-
ment of a woman’s desired ability to adapt and capacity to
self-manage. Conceptualization of healthy menopause
serves as a crucial step in improvement of health in
menopausal women, allowing for adapting adequate pre-
ventive and treatment strategies [33].
Although cardiovascular disease (CVD) remains one of
the leading causes of death and disability for both men and
women, our research underscores considerable sex differ-
ences in the occurrence of the various manifestations of
CVD. Using the long term follow-up from the prospective
population based Rotterdam Study, we showed that despite
similar lifetime risks of CVD at age 55 for men and
women, considerable differences in the first manifestation
exist. Men are more likely to develop coronary heart dis-
ease as a first event, while women are more likely to have
cerebrovascular disease or heart failure as their first event,
although these manifestations appear most often at older
ages [34]. Since strategies for prevention of stroke and
heart failure might differ from strategies for prevention of
coronary heart disease, to devise a sex-tailored primary
prevention program, knowledge about the first manifesta-
tion of CD is important.
A gender perspective on health and ageing
Based on 7 domains including chronic diseases, mental
health, cognitive function, physical function, pain, social
support, and quality of life, we developed a healthy ageing
score among women and men in the Rotterdam Study. In
all age categories, we found levels of healthy ageing score
to be lower in women compared with men. In both genders,
the healthy ageing score declined with increasing age,
albeit the decline was slightly steeper in women [35]. In an
attempt to characterize the relation between fertile life span
characteristics and mortality, we found that late first and
last reproduction were protective for all-cause mortality,
whereas a longer maternal lifespan, postmaternal fertile
lifespan, and endogenous estrogen exposure were harmful
for all-cause mortality [36]. Further, we used seven met-
rices of health factors and health behaviors to define the
concept of cardiovascular health in the Rotterdam Study.
We showed that optimal cardiovascular health was reached
by 9.3% of men and 10.4% of women in the Rotterdam
Study and was associated with both sex steroids and sex
hormone-binding globulin (SHBG) among men and
women [37]. To further assess the impact of androgen
levels on women’s cardiometabolic health, we formed a
multi-center study in which we assessed several car-
diometabolic features among women with polycystic ovary
syndrome (PCOS), women premature ovarian insufficiency
(POI), natural post-menopause women, and women with
regular menstrual cycles. This study affirmed the potent
effect of androgens on cardiometabolic features, indicating
that androgens should indeed be regarded as important
denominators of women’s health [38]. Also, we found that
women with POI exhibited an unfavorable cardiovascular
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risk profile, including higher abdominal fat, elevated
chronic inflammatory factors, and a trend toward increased
hypertension and impaired kidney function compared to
premenopausal women of middle age [39].
Heart failure and atrial fibrillation
The Rotterdam Study enabled accurate assessment of the
incidence and lifetime risk of heart failure and atrial fib-
rillation in an elderly population [40–42]. It was shown that
inflammation and resting heart rate is associated with risk
of heart failure [43, 44]. In addition we identified several
new risk factors of atrial fibrillation. We found that
markers of generalized atherosclerosis in persons without a
history of myocardial infarction or angina were associated
with a higher risk of atrial fibrillation [45]. Furthermore,
high-normal thyroid function [46] and higher levels of
dehydroepiandrosterone sulfate, a precursor in the biosyn-
thetic pathway of androgenic and estrogenic sex hormones
were associated with incidence of atrial fibrillation [47].
Among individuals free of CVD, we also found an asso-
ciation between epicardial fat, measured by CT scan, with
AF that was independent of traditional cardiovascular risk
factors, coronary atherosclerosis, left atrial size, and vari-
ous measures of adiposity [48]. In collaboration with sev-
eral community-based prospective studies we were able to
develop a prediction model for atrial fibrillation, only using
variables that are routinely collected in primary care set-
tings [49]. In a large collaborative study as part of the
CHARGE consortium, we investigated the genetic varia-
tion responsible for 6 traits related to cardiac structure and
function. We found two replicated loci for left ventricular
dimension and 5 replicated loci for aortic root size [50].
Another topic of interest was the search for genetic deter-
minants of several rhythm and conduction disturbances on
the ECG, notably RR-interval, QRS duration, and QT(c)-
interval, PR-interval, as well as atrial fibrillation and sud-
den cardiac death. For example, we identified several new
loci for PR interval [51], heart rate [52], and atrial fibril-
lation [53, 54] in meta-analyses from the CHARGE
consortium.
Type 2 diabetes
Type 2 diabetes (T2D) has become a global epidemic. We
took a comprehensive approach to calculate the lifetime
risk of the full range of glucose impairments, from nor-
moglycaemia to prediabetes, type 2 diabetes, and eventual
insulin use. At age 45 years, the remaining lifetime risk
was 48.7% for prediabetes, 31.3% for diabetes, and 9.1%
for insulin use. Our findings highlighted the substantial
burden of impaired glucose metabolism on population
health, emphasizing the need for more effective prevention
strategies [55]. Using multistate life table, we showed that
obesity in the middle aged and elderly is associated with a
reduction in the number of years lived free of diabetes and
an increase in the number of years lived with diabetes [56].
In a mendelian randomization study, we did not find evi-
dence for a causal role of serum gamma-glutamyltrans-
ferase on the risk of prediabetes or diabetes [57]. Among
inflammatory markers, we found EN-RAGE to be a novel
inflammatory marker for pre-diabetes, IL17 for incident
T2D and IL13 for pre-diabetes, incident T2D and insulin
therapy start [58]. Also we reported that serum apoCIII
levels as well as apoCIII-to-apoA1 ratio were associated
with incident diabetes independent of known risk factors
[59]. ADAMTS13, a novel homeostatic factor, was an
independent risk factor for incident prediabetes and type 2
diabetes [60]. In women, we found that low levels of sex
hormone-binding globuline and high levels of total estra-
diol were associated with increased risk of T2D, indepen-
dent of potential intermediate risk factors such as obesity,
glucose and insulin levels [57]. In both men and women,
serum dehydroepiandrosterone levels were associated with
lower risk of T2D, whereas no associations were found for
other hormones in either sex [57, 61]. Further, we provided
insights into potential biological mechanisms connecting
tobacco smoking to excess risk of T2D by investigating the
association between smoking and DNA methylation of
genes previously identified for diabetes. We found that
tobacco smoking is associated with differential DNA
methylation of the diabetes risk genes ANPEP, KCNQ1
and ZMIZ1 [62].
Cardiovascular risk factors and prediction
Endocrine, inflammatory and hemostatic factors and risk of
coronary heart disease were addressed in several studies.
Subclinical hypothyroidism was an independent risk factor
of atherosclerosis and myocardial infarction in older
women [63]. In a recent study, we compared the change in
the accuracy of risk predictions when newer risk markers,
representative of various pathophysiologic pathways, were
added to the established clinical risk predictors. Among the
biomarkers, improvements in coronary heart disease risk
prediction were most significant with the addition of
amino-terminal pro-B-type natriuretic peptide (NT-
proBNP) [64, 65]. Furthermore, plasma C-reactive protein
(CRP) and lipoprotein-associated phospholipase A2 (Lp-
PLA2) activity were independent predictors of coronary
heart disease [66, 67]. Earlier findings included the asso-
ciation of tissue plasminogen activator (TPA) with incident
coronary heart disease [68]. Using a comprehensive bio-
marker assay, we analysed multiple markers of inflamma-
tion among 800? individuals with incident coronary heart
disease [69]. We identified EN-RAGE as a novel
The Rotterdam Study: 2018 update on objectives, design and main results 811
123
biomarker for incidence of coronary heart disease, inde-
pendent of established risk factors and inflammatory
markers, such as C-reactive protein [69]. With respect to
the prediction of coronary heart disease, EN-RAGE
improved prediction significantly indicating that EN-
RAGE might be useful in CHD prediction [69]. Regarding
novel hemostasis risk factors, we found low ADAMTS13
activity to be associated with increased risk of coronary
heart disease, ischemic stroke, and all-cause and cardio-
vascular mortality beyond the traditional risk factors
[70–72]. Recently, we developed and validated a coronary
heart disease prediction model tailored for the aging pop-
ulation based on competing risk methodology [73]. Also,
we have shown that the non-laboratory based model, based
on body shape index, could predict risk of cardiovascular
disease as accurately as one that relied on laboratory-based
values among men [74].
Non-invasive measures of atherosclerosis
Multiple studies focused on the predictive value of non-
invasive measures of atherosclerosis for risk of coronary
heart disease. Strong associations with risk of coronary
heart disease were found for carotid intima-media thick-
ness [75], pulse wave velocity [76], and coronary calcifi-
cation as assessed by electron-beam CT [77]. The relatively
crude measures directly assessing plaques in the carotid
artery and abdominal aorta predict coronary heart disease
equally well as the more precisely measured carotid intima-
media thickness [78]. We also found carotid stiffness to be
associated with incident stroke independently of cardio-
vascular risk factors and aortic stiffness [79]. In persons at
intermediate risk of cardiovascular disease, coronary artery
calcium provided the best increment in coronary heart
disease risk prediction and stratification (to reclassify per-
sons into more appropriate coronary risk categories)
[64, 80, 81]. The burden of coronary calcification also
provides incremental predictive information for heart fail-
ure, but nor for cerebrovascular disease [82, 83]. In a large
meta-analysis of 5 population-based studies, including the
Rotterdam Study, we showed that coronary artery calcium
was present in approximately one-third of women catego-
rized as being at low CVD risk based on the new ACC/
AHA guidelines. Presence of coronary artery calcium
among low-risk women was associated with an increased
risk of CVD and led to modest improvement in prognostic
accuracy compared with traditional risk factors [84].
Genetic studies
Genetic studies included candidate gene studies [85] and
more recently genome-wide association studies of clinical
disease and risk factor phenotypes. So far we have
contributed to more than 100 Genome-wide association
(GWA) studies in the field of cardiovascular disease. These
GWA studies are primarily conducted in the framework of
the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium [86, 87] however in
many instances we include further studies. We identified 3
genetic loci associated with uric acid concentration and
gout [88]. Three loss-of-function variants in HAL gene
were found to associate with histidine levels [89] but not
with coronary heart disease. We also identified a significant
association between the UMOD gene which encodes
Tamm–Horsfall protein and chronic kidney disease [90].
We found four genes for systolic blood pressure, six for
diastolic blood pressure and one for hypertension [91–93].
We found multiple loci that influenced erythrocyte phe-
notypes in the CHARGE Consortium [94]. In a meta-
analysis in more than 80,000 individuals from 25 studies,
we identified 18 loci for CRP levels. The study highlighted
immune response and metabolic regulatory pathways
involved in the regulation of chronic inflammation [95].
Novel associations of 12 low-frequency exonic variants
with plasma levels of factor VII, factor VIII, and von
Willebrand factor were also detected [96, 97]. The asso-
ciation with these variants was independent of the previ-
ously identified common variants associated with these
traits, and the effect sizes were larger. We performed the
first GWA study of ADAMTS13 activity, identifying
independent associations with three common variants at the
ADAMTS13 locus, as well as one common variant at the
SUPT3H locus [98]. Additionally, we used a genotyping
array focused on rare exonic variants to identify three
independent rare variants in the ADAMTS13 gene associ-
ated with ADAMTS13 activity [98]. We have also identi-
fied genetic loci associated with the measures of subclinical
atherosclerosis burden. Our genome-wide association
studies on the 3 measures of subclinical atherosclerosis
identified several new genetic loci [99–101]. Our exome-
wide association meta-analysis demonstrated that protein-
coding variants in APOB and APOE associate with mul-
tiple subclinical atherosclerosis traits as well as clinical
coronary heart disease. We have contributed to GWA
studies on coronary artery disease [102, 103]. Also, we
found that 152 known coronary heart disease SNPs
improved the prediction of prevalent but not incident
coronary heart disease. This difference may be explained
by biases related to the use of prevalent rather than incident
coronary heart disease in genome-wide association studies
[104]. In addition, by using genome-wide methylation data,
we found an effect of tobacco smoking on DNA methy-
lation of 12 coronary artery disease-related genes [105] and
associations of blood lipid concentrations with methylation
at several metabolic disease-related genes [106], and thus
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providing novel insights in the pathways underlying car-
diometabolic disease.
Thus far, a large number of genetic variants have been
identified by GWAS that contribute to the induction and
development of cardio-metabolic diseases. Nevertheless,
the vast majority of the identified variants map to the non-
coding regions of genome that their biological relevant to
the disease remain unclear. Non-coding RNAs play regu-
latory roles in various biological processes and cellular
contexts. We identified a number functional variants in
microRNA-genes and microRNA binding sites on the
3U´TR of coding genes that affect miRNA gene regulation
and explain some of the observed associations from GWAS
of cardio-metabolic phenotypes [107–109].
Nutrition and lifestyle
We found that dietary fat intake palmitic acid, which
accounts for half of the total saturated fat intake, was
associated with an increased risk of coronary heart disease,
as was substitution of total saturated fat with animal protein
[110]. We did not confirm a consistent association between
dietary fat composition and body fat distribution, but we
found that total polyunsaturated fatty acids, and in partic-
ular n-6 polyunsaturated fatty acids intake, was associated
with lower inflammatory profile [111]. We also conducted
several studies on the association between nutrition and
cancer. We showed that n-3 polyunsaturated fatty acids
intake were associated with increased risk of colorectal
cancer, but this association was modified by dietary fiber
intake [112]. We did find that dietary polyunsaturated fat
intake modified the association between total serum
cholesterol levels and the risk of colorectal cancer
[113, 114]. We also studied whether dietary mineral intake
were associated the risk of lung cancer and found that high
dietary zinc and iron intake were associated with a reduced
risk of lung cancer [115]. In addition to individual nutrient
analyses, we performed several studies on a priori and a
posteriori defined dietary patterns and health outcomes in
The Rotterdam Study. For example, we found that adher-
ence to the Dutch dietary guidelines was inversely asso-
ciated with 20 year mortality in particular due to
cardiovascular disease mortality [116]. We also found that
a health conscious dietary pattern, characterized by high
intake of fruits, vegetables, poultry ranch fish, may have
benefits for bone mineral density. Contrary, adherence to a
Processed dietary pattern, characterized by high intake of
processed meat and alcohol, was associated with lower
bone mineral density [117]. Additionally, we evaluated if
dietary patterns that explain most variation in bone mineral
density and hip bone geometry are associated with fracture
risk. We observed that a pattern high in fruit,
vegetables and dairy could be associated with lower frac-
ture risk because of high bone mineral density [118].
As part of the CHANCES consortium, we found that
adherence to a healthy diet was not associated with cog-
nitive decline [119] but that adherence to the WCRF/AICR
Dietary Recommendations for cancer prevention was
associated with a lower risk cancer in older individuals, in
particular colorectal and prostate cancer [120].
For physical activity, we observed that higher levels of
physical activity were associated with increased life
expectancy and more years lived without CVD. Of the
different types of physical activity included in the study,
cycling provided high effects in both men and women
[121]. In line with these results, during a 15-year follow-
up, it was observed that high physical activity was asso-
ciated with less coronary heart, mainly explained by
cycling and domestic work [122]. Furthermore, it was
observed that sedentary behavior was, independent of other
physical activity, a risk factor for all-cause mortality [123].
Methods update
Clinical follow-up
Information on clinical cardiovascular outcomes is col-
lected through an automated follow-up system. The follow-
up system involves linkage of the study base to digital
medical records from general practitioners in the study area
and subsequent collection of letters of medical specialists
and discharge reports in case of hospitalisation. With
respect to the vital status of participants, information is also
obtained regularly from the municipal health authorities in
Rotterdam. After notification, cause and circumstances of
death are established by questionnaire from the treating
physicians. Clinical cardiovascular outcomes are adjudi-
cated according to established definitions based on inter-
national guidelines by study physicians and medical
specialists in the field affiliated with the Rotterdam Study.
Methods of follow-up data collection, adjudication of
events, and definitions of cardiovascular end points have
been described in detail previously in this journal [124].
Systematic follow-up data collection is done for the
occurrence of cardiovascular mortality, coronary heart
disease (including coronary death, myocardial infarction,
and coronary revascularization procedures), heart failure,
atrial fibrillation, and sudden cardiac death [124]. Diabetes
mellitus is defined based on guidelines of the American
Diabetes Association and the World Health Organization.
We defined incident diabetes as fasting plasma glucose
level C 7.0 mmol/L, or the use of oral antidiabetic medi-
cation or insulin, or treatment by diet and registered by a
general practitioner as having diabetes.
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Cardiovascular risk factors
Besides traditional cardiovascular risk factors, five major
groups of putative risk factors for cardiovascular conditions
are examined. The first group are lifestyle factors, includ-
ing dietary factors, physical activity, smoking, sleep and
vitamin D (as described above). The second are endocrine
factors, including diabetes, sex hormones, thyroid gland
and adrenal gland hormones and natriuretic peptides (e.g.
[46, 47, 63–65]). The third group comprises factors
involved in hemostasis, inflammation and endothelial
function (e.g. [66, 125, 126]). The fourth group covers
genetic factors. In addition to the candidate gene approach,
studies are more recently conducted through the genome-
wide association approach (e.g. [50–54, 88, 90–95,
99–103, 125, 127–129]). In genome-wide association
studies, data from the Rotterdam Study are often combined
with those from other studies in the context of the large
collaborative CHARGE consortium [86, 87]. Within the
fifth group we are applying both proton Nuclear Magnetic
Resonance (1H NMR) and Mass Spectrometry (MS) for
metabolic profiling in 2000 participants of the Rotterdam
Study including nearly 200 incident cases of coronary heart
disease. Furthermore, in this context, special attention has
been given to the contribution of different risk factors in
relation to cardiovascular disease in women. Data has been
collected to evaluate the impact of specific periods of
potential vulnerability across a woman’s lifespan; menar-
che, pregnancy, and menopause. Also, DNA methylation
can regulate gene expression without altering the under-
lying DNA sequence and is now emerging as a promising
molecular strategy for risk stratification for complex dis-
ease, including cardiovascular disease. Using the Illumina
Infinium HumanMethylation450 array, we have generated
DNA methylation profiles of * 480,000 CpG sites in
In * 1000 samples of the RS-III.
Non-invasive measures of atherosclerosis
At baseline and follow-up examinations, ultrasonographic
assessments of carotid intima-media thickness and carotid
plaques were conducted in all participants [75]. At these
examinations, also measurements of the ankle-brachial
index and aortic calcification (on X-rays of the lumbar
spine) were obtained [78]. Carotid–femoral pulse wave
velocity, a measure of aortic stiffness, was measured in all
*participants of RS-I-3, RS-II-1, and RS-III-1 with an
automatic device [76]. Measurements of coronary calcifi-
cation by electron-beam CT and more recently by MDCT
were conducted from 1997 onwards in RS-I and RS-II
[77, 80]. From 2003 to 2006, MDCT was used to also
quantify calcification in the aortic arch and carotid arteries
in RS-I and RS-II. Measurement of carotid plaque
components using MRI was done from 2007 to 2012 in all
participants from RS-I, RS-II and RS-III with carotid wall
thickening on conventional carotid ultrasound. Repeated
MRI measures over time were obtained in RS-I and RS-II.
Electrocardiographic, echocardiographic and other
ultrasound measurements
At every exam, a 12-lead 10-s resting ECG is made and
processed by the Modular ECG Analysis System
(MEANS) to obtain a series of ECG measurements [130].
Abdominal aortic diameters were measured by ultrasound
at RS-I-1, and from 2002 (RS-I-4) onwards in all three
Rotterdam Study cohorts. Also from 2002 onwards (RS-I-
4), repeated echocardiographic measurements are con-
ducted of structural and functional left heart parameters
[131]. From 2009 (RS-I-5) onwards, measurements of
structure and function of the right heart are also collected,
including estimates of pulmonary artery pressure. In the
same round a 3-min resting ECG was measured in all
participants.
Nutrition and lifestyle
Dietary intake data have been collected in RS-I-1, RS-I-5,
RS-I-6RS-II-1, RS-II-3, RS-II-4, and RS-III-1 by using
semi-quantitative food-frequency questionnaires (FFQ). In
RS-I-1 and RS-II-1, participants completed a checklist
about foods and drinks they had consumed at least twice a
month during the preceding year and a standardized
interview using a validated 170-item semi-quantitative
FFQ [132]. For the later waves and cohort, a more com-
prehensive 389-item FFQ was used during the visits as
described in detail previously [133–136]. For all cohorts,
nutrient intake data were calculated using the Dutch Food
Composition Tables, in close collaboration with the
Department of Human Nutrition, Wageningen University,
the Netherlands. In RS-I-III, RS-I-5, RS-II-3 and RS-III-I,
physical activity data was assessed by means of an adapted
version of the Zutphen Physical Activity Questionnaire and
the LASA Physical Activity Questionnaire [137–139]. The
questionnaire contained questions on walking, cycling,
gardening, diverse sports, hobbies and on housekeeping.
According to time spent in light, moderate and vigorous
activity, metabolic equivalents of task were calculated.
Furthermore, we are implementing objective measurement
of physical activity with triaxial accelerometers in all
participants.
Frailty index
As a proxy for overall health we developed a frailty index
for the Rotterdam Study, based on predefined criteria
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[140]. A frailty index is based on the accumulation of
health deficits, which can include an unspecified number of
symptoms, diseases, laboratory measurements or disabili-
ties, as long as they are health and age related [141]. The
severity of frailty is represented by the number of deficits
and is expressed on a continuous frailty index score, cal-
culated as the ratio of the deficits present to the total
number of variables considered (range 0–1). We calculated
a frailty index based on 45 health-related variables, related
to cognition, functional status, diseases and biomarkers, for
over 11,000 participants. The frailty index showed good
construct and criterion validity (e.g. strong association with
mortality) [142].
For additional EJE references please see [27, 143–165].
Dermatological diseases
Objectives
Dermatoepidemiologic research in the Rotterdam Study
focuses on the frequency of the most common skin con-
ditions as well as on genetic and environmental factors
associated with these skin diseases. The emphasis is on
cutaneous malignancies such as basal and squamous cell
carcinomas (BCC and SCC, respectively) and their pre-
cursor lesions (actinic keratosis), inflammatory dermatoses
such as eczema and psoriasis, and varicose veins. Also, we
examine the frequency and determinants including genetics
and environmental exposures of skin aging (pigmentation,
wrinkling and photodamage) and other visible traits in
collaboration with the department of Genetic Identification.
Recently, we have introduced optic measures of UV
exposed and non-exposed to assess whether they can
function as biomarkers of skin and internal diseases.
Methods
In 2010, dermatology studies were introduced in the Rot-
terdam Study. To the home interview several items have
been added questioning ultraviolet light exposure, history
of (personal and familial) psoriasis, history of skin cancer,
the diagnostic criteria for atopic eczema, adjusted diag-
nostic criteria for psoriatic arthritis. More recently, items
on skin care and seborrheic dermatitis/dandruff were
added.
A full body skin examination by physicians trained in
dermatology with a focus on the most common skin dis-
eases is the core contribution of dermatology. The clinical
presence and extent of specific skin diseases (i.e., actinic
keratosis, malignancies, psoriasis, seborrheic dermatitis,
xerosis, hand and flexural eczema, alopecia, and signs of
chronic venous insufficiency based on the ‘C’ of the CEAP
classification) at time of examination is assessed in a
standardized fashion. Other dermatological diseases will
just be noted.
The extent of skin aging as a global score and broken
down in different aspects such as wrinkling, pigmentary
spots, and teleangiecatsia are scored using a validated
photonumeric scales and computer algorithms. The Nor-
wood-Hamilton classification and the Ludwig classification
is used for male and female pattern hair loss, respectively.
Fully standardized 3-dimensional photographs (Premier
3dMDface3-plus UHD, Atlanta, USA) of the face are taken
to further assess skin characteristics including sagging,
wrinkling at different sites, teleangiectasia and pigmented
spots. The colour of the facial skin and at the inner side of
the upper arm are measured using a spectrophotometer
(Konica Minolta Sensing, spectrophotometer CM-700d,
Singapore). Recently, we have included a screening venous
ultrasound examination of the lower extermities assessing
the deep and superficial venous system. Also, we added
skin swabs of the nasolabial fold to investigate the diversity
of the microbioom across a large population and assess its
relationship with other (skin) diseases.
As for other cancers, pathology data of the cutaneous
malignancies is obtained from linkage to the national
cancer registry and the Dutch pathology database
(PALGA). In a further attempt to identify cohort members
with psoriasis, medical files and dispenses at pharmacies
have been investigated resulting in over 350 psoriasis
cases.
Major findings
In the first follow-up study including the skin examinations
of more than 2000 cohort members, showed that actinic
keratosis is very common in this elderly population (AK
prevalence was 49% for men and 28% for women) [166].
After adjusting for other factors, baldness in men was
associated with a strongly increased risk of actinic
keratosis.
A recent update yielded more than 1500 participants
with a history of BCC, 450 with a SCC and 150 with a
melanoma. We have demonstrated that approximately 30%
of people with a BCC develop multiple tumors with
5 years and have developed a prediction model to identify
these high risk patients [167]. A first genetic analysis could
not confirm any of the existing BCC polymorphisms to be
associated with the development of multiple BCC [167]. A
subsequent GWAS in an international consortium could not
observe the association between common variants and
multiple keratinocytic cancers [168]. In new and bigger
international collaboration these findings are being re-
evaluated. We have presented the first GWAS on actinic
keratosis [169]. Several skin color genes such as IRF4,
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MC1R, ASIP and BCN2 were significantly associated with
these premalignant skin lesions independently from skin
color. Using compound heterozygosity analysis, several
other pigment related genes were identified for AK [170].
In a candidate gene study in almost 6000 people, we
confirmed known and identified new variants associated
with digital skin colour extraction. Of the two new skin
color genes, the genetic variants in UGT1A were signifi-
cantly associated with hue and variants in BNC2 were
significantly associated with saturation [171]. In the
International Visible Trait Genetics Consortium, we iden-
tified novel pigmentation genes confirmed by functional
follow up [172]. Several pigmentation genes were also
significantly associated with the presence of pigmented
facial spots in a GWAS [169].
Among over 3000 individuals several components of
skin aging have been investigated. The most recent finding
is a study showing that Individuals carrying the homozy-
gote MC1R risk haplotype looked on average up to 2 years
older than non-carriers MC1R [173]. Also, we have
demonstrated that digitally extracted wrinkle area from
facial 3D photo’s was higher in men (median 4.5%, [in-
terquartile range (IQR): 2.9–6.3]) than in women (3.6%,
[IQR 2.2–5.6]). Age was the strongest determinant, and
current smoking and lower body mass index were also
statistically significantly associated with increased wrin-
kling. Pale skin color showed a protective effect and, in
men, sunburn tendency was associated with less wrinkling.
In women, low educational levels and alcohol use associ-
ated with more wrinkling, while female pattern hair loss
and a higher free androgen index were associated with less
wrinkling [174].
The psoriasis patients within the Rotterdam Study have
predominantly mild disease. The distribution of subclinical
artherosclerosis measures as well as the cardiovascular
events were comparable between the 262 psoriasis patients
and the reference population [175]. However, psoriasis
patients were significantly more likely to have signs of
nonalcoholic fatty liver disease based on ultrasonography
than their controls after adjusting for potential confounders
[176]. Moreover, psoriasis patients were more likely to
have liver fibrosis than controls comparing Fibroscan data
[177].
Endocrine diseases
Objectives
The main objective of the programme of endocrine epi-
demiology research is to study frequency and etiology of
major disorders of the endocrine glands (pituitary, repro-
ductive, thyroid, parathyroid, adrenal, and neuro-endocrine
pancreas). These include diabetes mellitus, hypo- and
hyper-thyroidism. The evaluation of risk factors for the
above mentioned conditions includes serum measurements
(such as classical hormones and other endocrine mole-
cules), and genetic determinants of endocrine diseases and
traits. In addition, consequences of these endocrine disor-
ders are studied in relation to mortality and aging related
diseases, including cardiovascular disease, eye diseases,
skin diseases, neurocognitive decline and cancer.
Major findings
We demonstrated that high-normal thyroid function is
associated with an increased risk of atrial fibrillation [46]
and subsequently showed that higher FT4 levels are asso-
ciated with an increased risk of sudden cardiac death, even
in euthyroid participants [178]. The absolute 10-year risk
of SCD in euthyroid participants increased from 1 to 4%
from low-normal to high-normal FT4 levels. A higher
thyroid function does not only have negative consequences
for the cardiovascular system, since we also showed that a
higher thyroid function is associated with increased risk of
kidney function decline [179], an increased risk of any
solid, lung, and breast cancer [180], as well as an increased
risk of AMD [181]. Finally, a high and high-normal thyroid
function is also associated with increased risk of develop-
ing depression in the elderly [182] and with an increased
dementia risk [183]. Interestingly, thyroid function is not
related to vascular brain disease as assessed by MRI,
suggesting a role for thyroid hormone in nonvascular
pathways leading to dementia.
Whereas these data suggest that a higher thyroid func-
tion can be detrimental during the aging process, other
studies have shown negative consequences of a lower
thyroid function as well. We recently showed that a lower
thyroid function is associated with an increased risk of
NAFLD [184], as well as that a low and low-normal thy-
roid function are risk factors for incident diabetes, espe-
cially in individuals with prediabetes [185]. IN previous
studies we already demonstrated that subclinical hypothy-
roidism is also an independent risk factor of atherosclerosis
and myocardial infarction in older women [63]. Also for
gait, both low and high thyroid function are associated with
alterations in Global gait, Tandem, Base of support and
velocity [186].
Future studies will focus on the challenge of defining
optimal thyroid function for relevant clinical outcomes and
determine which subgroups need specific reference ranges.
As part of the Thyroid Studies Collaboration, we recently
published four individual-participant data analyses. By
analyzing individual participant data from 13 prospective
cohorts (70,298 participants) we demonstrated that sub-
clinical hyperthyroidism is associated with an increased
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risk of hip and other fractures, particularly among those
with TSH levels of less than 0.10 mIU/L and those with
endogenous subclinical hyperthyroidism [187]. An analysis
combining data from 17 cohorts and lead by the Rotterdam
Study did not show a higher risk of stroke with subclinical
hypothyroidism except in participants younger than
50 years of age [188], whereas higher levels of TSH within
the reference range may decrease the risk of stroke [189].
A combined analysis in 14 cohorts focusing on risk of
coronary heart disease showed no relationship of TSH
levels within the reference range and risk of CHD events or
CHD mortality [190].
Much of the work of this research is made possible by
large-scale collaboration in consortia, some of which focus
on one particular disease or trait while others are more
broad spectrum strategic collaborations (e.g., CHARGE,
ENGAGE). We are part of several such large consortia
studying genetic and epidemiological risk factors for dia-
betes (MAGIC), and thyroid disease (CHARGE and TSC).
Major GWAS findings
The main factors that influence the relationship between
thyroid hormone and concentrations of TSH in our popu-
lation-based cohort study are age, smoking, BMI, TPOAb
levels, and common genetic variants [191]. In a meta-
analysis of GWAS data on TSH levels and free T4 levels
derived from up to 26,000 subjects, 26 loci were identified
explaining 2–5% of the genetic variation of TSH and fT4
respectively [192]. There was only limited overlap between
the loci for TSH and fT4, and evidence was obtained for 5
loci to have sex-specific effects. A GWAS meta-analysis
focusing on TPO autoantibodies (an important clinical
marker for the detection of early AITD) in 16 cohorts
identified five newly associated loci, three of which were
also associated with clinical thyroid disease. With these
markers we identified a large subgroup in the general
population with a substantially increased risk of TPOAbs
[193]. A follow-up study identifying 4 additional loci
associated provided further insight into the genetic under-
pinnings of hypothyroidism. A Genetic Risk Score showed
strong and graded associations with markers of thyroid
function and disease in independent population-based
studies [194].
Methods update
Several specific biomarker assessments in blood/ser-
um/plasma and urine are done for the diagnosis and eval-
uation of risk factors of endocrine and metabolic diseases
(e.g., glucose, TSH, freeT4). Fasting blood samples are
collected along with challenged samples as part of a glu-
cose tolerance test. Saliva is collected before and after a
dexamethasone-suppression test. Finally, validated ques-
tionnaires evaluating nutrient intake (e.g., calcium and
vitamins) and activities of daily living, allow to evaluate
the role of environmental factors in endocrine conditions
and diseases of the elderly.
For additional EJE references please see [195–197].
Locomotor diseases
Objectives
The main objective of the program of locomotor epi-
demiology research is to study frequency and etiology of
major disorders of the musculoskeletal system including
osteoporosis (OP), osteoarthritis (OA), sarcopenia and
chronic musculoskeletal pain. The evaluation of risk fac-
tors for the above mentioned conditions includes genomic
determinants; serum biomarkers; nutrients; anthropomet-
rics, imaging of bones and joints by X-ray and MRI; and
densitometry and body composition quantification by
DXA, and pQCT. In addition, these locomotor conditions
are studied in the context of other aging related metabolic
diseases, including cardiovascular disease and diabetes.
Such deep musculoskeletal phenotyping makes the Rot-
terdam Study a unique resource to study determinants of
OP, OA, sarcopenia, and chronic pain and constitutes one
of the largest such dataset in the world.
Major findings
Osteoporosis and bone health
We have obtained digitized X-rays for many participants at
the several time-points of follow-up, and have applied three
different methods to score vertebral fractures: quantitative
morphometry (QM), semi-quantitative morphometry (SQ),
and the algorithm based qualitative (ABQ) method [198].
A recent comparison of QM assisted by SpineAnalyzer
(SA) software and ABQ, showed that vertebral fracture
prevalence differed substantially between the methods,
with similar findings being done by the Canadian working
group on vertebral fx assessment of the CaMos study.
Vertebral deformities misclassified as fractures, typically
observed in the SA-QM group classified as mild (Grade 1)
inflate drastically the prevalence, and are partly responsible
for the observed differences across methods. Re-examining
SA-QM grade 1 by assessing endplate depression (the
ABQ hallmark) helps discriminating deformities from real
fractures. Therefore we proposed this approach to be
implemented in radiological clinical practice, thus helping
practitioners to assess better the indication of osteoporosis
therapy [198].
The Rotterdam Study: 2018 update on objectives, design and main results 817
123
We determined the relationship of metabolic syndrome
and bone health [199] establishing that in contrast to T2D
no association with fracture risk was identified despite the
fact that, among the metabolic syndrome components,
glucose levels were associated with high FN-BMD, high-
lighting the need to preserve glycemic control to prevent
skeletal complications. Further, we have looked at the
relationship between uric acid (UA) and bone health out-
comes [200] showing how higher levels of serum UA are
associated with higher BMD (at the expense of thicker
bone cortices and narrower bone diameters) also in inter-
action with age and vitamin C intake.
Such relationship between bone health and nutritional
factors has been extensively examined within the Rotter-
dam Study. In relation to specific nutrients, we established
a plausible favorable relation between high vitamin A
intake from the diet with fracture risk in overweight sub-
jects [201]. We also determined that a diet high in acid-
forming nutrients (e.g., proteins) may be detrimental to
bone health in participants with high intake of dietary fibre
[202]. Further, we identified dietary patterns influencing
bone health, where beneficial effects on higher BMD were
seen with ‘‘Health conscious’’ patterns in contrast to pat-
terns characterized ‘‘Processed food’’ indicate potential
susceptibility to presenting low BMD [117]. In addition,
we could establish how specific patterns are associated
with bone configurations influencing fracture susceptibility
[118]. Finally, we developed a food group-based score
translated into a BMD-Diet score, capable of profiling
groups of food associated with higher/lower BMD levels;
of great potential to be adapted in dietary guidelines
focused on promoting healthy aging [203].
Although extreme phosphate levels have been associ-
ated with mineralization defects and increased fracture risk
it was not known whether phosphate levels within normal
range are related to bone health in the general population.
In the Rotterdam Study we found that serum phosphate was
positively related to fracture risk independently from BMD
and phosphate intake after adjustments for potential con-
founders and these findings were replicated in the US
Osteoporotic Fractures in Men (MrOS) study [204].
Phosphate and lumbar spine but not femur neck BMD were
negatively related in men only. Our findings suggest that
higher phosphate levels even within normal range might be
deleterious for bone health in the normal population.
Osteoarthritis
Over the last years, we have scored X-ray all radiographs
of knee, hip and hand of RS I, II and III for osteoarthritic
features including up to 20 years of follow-up radiographs.
In addition, we have (bilateral) knee MRI images available
for a subset (± 1000) individuals of RS III, including a
longitudinal follow-up MRI after 6 years. In addition, pain
sensitivity measurements have been performed including a
quantitative assessment of heat sensitivity on the arm using
a standardized device (TSA-II neurosensory analyzer,
Medoc), and indications of (wide-spread) pain in any part
of the body using a manikin.
Over the last 2 years several established and novel risk
factors for OA were examined. No clear association
between vitamin serum levels and prevalent, incident or
progressive knee, hip or hand OA was observed in the
Rotterdam Study and subsequent meta-analysis [205]. We
showed for the first time that a marker of tissue inflam-
mation, matrix metalloproteinase-dependent degradation of
C-reactive protein (CRPM), predicts the risk of OA pro-
gression. This risk was independent of the established
biomarkers uCTX-II and COMP [206]. Biomarkers of
atherosclerosis were not related to progression of knee
osteoarthritis [207]. Furthermore, individuals with cam
deformity and those with acetabular dysplasia, two hip
shape deformities, were shown to be at higher risk for
developing OA; these associations were independent of
other well-known risk factors [208]. RNA expression in
blood was found to associate with peripheral inflammation
in the knee, as measured by joint effusion [209].
A large-scale transcriptome-wide study of muscle
strength in human adults identified a total of 221 genes, of
which circulating expression levels were associated with
muscle strength. This study confirmed associations with
known pathways involved in muscle and provides new
evidence for over half of the genes identified [210].
Chronic musculoskeletal pain
The relationship between the presence of chronic pain and
brain volumetrics was studied in the largest study to date.
Grey matter volume of the temporal and frontal lobes and
the hippocampus were found to be smaller in women with
pain compared to those without pain, indicated involve-
ment of emotional processing. The volumetric differences
found indicated a sex-specific neuroplasticity in chronic
pain [211]. Lower sex hormone levels were found to be
associated with chronic musculoskeletal pain, independent
from lifestyle and health-related factors in women, sug-
gesting that sex hormones play a role in chronic pain and
should be taken into account when a patient presents with
chronic pain [212]. Chronic joint pain in the lower body
was found to be associated with gait differences indepen-
dent from radiographic osteoarthritis, indicating that gait
assessment may help in identifying individuals with OA
from those having pain due to other causes [213]. Indeed,
asymptomatic radiographic hip osteoarthritis was found to
be associated with gait differences [214] especially in
women. Central sensitization, as measured by thermal
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quantitative sensory testing (QST) was shown be present in
community-dwelling elderly individuals suffering from
self-reported chronic pain. In addition, several determi-
nants influencing thermal QST measurement were identi-
fied [215].
Major GWAS findings
In a meta-analysis of[ 21,000 individuals, we identified
six loci to be associated with cartilage thickness, a so-
called endophenotype for osteoarthritis [216]. The most
prominent four novel associated genetic loci were located
in/near TGFA (rs2862851), PIK3R1 (rs10471753), SLBP/
FGFR3 (rs2236995), and TREH/DDX6 (rs496547), while
the other two (DOT1L and SUPT3H/RUNX2) were pre-
viously identified. Exome sequencing data (n = 2050
individuals) indicated that there were no rare exonic vari-
ants that could explain the identified associations. This is
the first report linking TGFA to human OA, which may
serve as a new target for future therapies.
In addition, we identified a variant in the protein-kinase
C gene to be associated with neuropathic pain symptoms
after total joint replacement highlights [217].
We performed within an international consortium a
meta-analysis of GWA studies for whole body lean body
mass which consists primarily of skeletal muscle mass, and
found five genetic loci to be significantly associated. The
loss of lean mass with aging which may lead to a condition
called ‘sarcopenia’ is associated with physical disability,
falls and fractures, poor quality of life and death [218].
In the field of osteoporosis we identified through leading
participation in international consortia less-frequent vari-
ants in EN1, the first gene identified combining whole-
genome sequencing and GWAS in the field of osteoporosis
[219]. Similarly, the Rotterdam Study made part of the first
epigenome-wide association study in relation to BMD
[220]. Furthermore, we co-lead the discovery of rare cod-
ing variants influencing human stature identified in a meta-
analysis comprising more than[ 700,000 individuals
[221].
Liver diseases
Objectives
The objective of liver research in the Rotterdam study is
concentrated on establishing the prevalence, incidence, risk
factors and prognosis of liver diseases in the general pop-
ulation. The two main liver traits of interest are non-alco-
holic fatty liver disease (NAFLD) and liver fibrosis.
NAFLD is considered the hepatic manifestation of the
metabolic syndrome and has become the most common
chronic liver disease in Western countries in parallel with
epidemics of obesity and type II diabetes mellitus. NAFLD
comprises the spectrum from simple steatosis (i.e. fatty
liver) to non-alcoholic steatohepatitis (i.e. NASH due to
hepatic inflammation), fibrosis, cirrhosis, liver failure and
hepatocellular carcinoma. It is estimated that about 25%
progress to NASH and more severe stages thereafter [222].
In high-risk populations with metabolic syndrome and
obesity, NAFLD appears prevalent in up to 70% [223], a
very worrisome trend indeed. Despite over 500 ongoing
clinical trials in NAFLD and NASH (www.clinicaltrials.
gov), no drug has yet been registered for use in NAFLD
patients. Hence the cornerstone of treatment continues to
consist of nonspecific life style modifications through
weight loss and exercise. We aim to study to what extent
the following factors play a role in NAFLD occurring in
the general and hence unselected population: components
of the metabolic syndrome, obesity, dietary composition,
dietary patterns, body composition and sarcopenia, gut
microbiome, genetic predisposition and cardiovascular
morbidity. With this, we aim to gain more insight into the
pathogenesis and provide rationale for more specific life
style interventions.
Fibrogenesis of the liver is most probably not only the
result of well-known liver diseases, such as viral hepatitis,
alcoholic liver disease or NAFLD, but rather a complex
interaction between a genetic predisposition and these liver
disorders. Liver research in the Rotterdam Study will
concern the association between these known causes of
liver disease and the occurrence, magnitude, and progres-
sion of fibrosis in combination with genetic and environ-
mental factors.
Methods
Abdominal ultrasound
From February 2009 onwards (cohorts RS-I-5, RS-II-3,
RS-III-2, RS II-4 and currently ongoing RS-IV-1), trained
technicians perform abdominal ultrasonography in Rotter-
dam Study participants. The liver parenchyma, biliary
tract, gall bladder, spleen, pancreas and kidneys are eval-
uated in combination with Doppler examination of hepatic
veins, hepatic artery and portal vein. All images are stored
digitally and are reevaluated by an expert hepatologist
trained in hepatic ultrasonography.
Assessment of steatosis
The diagnosis and grading of liver steatosis is based on
ultrasonographic liver brightness, hepatorenal echo con-
trast, deep attenuation and vessel blurring [224].
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Non-alcoholic fatty liver disease is diagnosed by pres-
ence of hepatic steatosis on ultrasound and the exclusion of
excessive alcohol consumption, presence of viral hepatitis,
use of steatogenic agents and recent bariatric surgery.
Assessment of fibrosis
Ultrasonographic evaluation of the liver parenchyma and
liver surface is performed in order to assess severe fibrosis
and/or cirrhosis. Additionally, sonographic signs of portal
hypertension are studied (i.e. splenomegaly, venous col-
laterals, portal vein diameter and flow, hepatic venous flow,
and the presence of ascites).
To assess and quantify the grade of fibrosis, trained
technicians perform transient elastography in all partici-
pants by the Fibroscan. This test measures non-invasively
and quantitatively the liver stiffness using an ultrasonic
transducer which transmits a vibration wave through the
liver. The velocity of the ultrasonic wave is measured in
kPa and correlates directly with liver tissue stiffness and
ultimately, degree of liver fibrosis [225, 226].
Determinants of interest
The association between factors known to influence liver
function and the occurrence of steatosis and fibrosis are
being studied. Additionally, the association of these con-
ditions with age, gender, nutritional intake, concurrent
alcohol intake, (risk factors for) viral hepatitis, BMI, waist-
to-hip ratio, serum glucose, insulin, and diabetes mellitus,
hypertension, serum cholesterol, triglycerides, dietary
composition, macronutrients, dietary patterns, sarcopenia,
body composition, and gut microbiome are investigated.
All clinical information is obtained by interview (updated
with liver specific questions) and clinical examination.
More recent efforts are focused on identifying common
genetic variants associated with liver steatosis and/or
fibrosis.
Main findings
We found a high prevalence of NAFLD of 35.1% within
the Rotterdam Study population [227]. Main risk factors
for NAFLD were found to be age, decreased physical
activity lever, smoking, increased waist circumference,
glucose intolerance, hypertension, and hyperlipidemia.
Inversely, the risk of NAFLD seems to decrease after statin
therapy [228]. Furthermore, using our ultrasound data as
reference, we examined the performance of the well-known
fatty liver disease index (FLI, based on waist circumfer-
ence, BMI, triglyceride and gamma-glutamyltransferase
(GGT) levels) in the Rotterdam Study population, and
found that the FLI is a highly valid tool to predict NAFLD
[229]. In another study, we found that all serum liver
enzymes are related to all-cause mortality, as well as
specifically cardiovascular (GGT) and cancer-related (al-
kaline phosphatase and aspartate aminotransferase) mor-
tality [230]. Moreover, we have examined the role of
genetic factors in the multifactorial etiology of liver
fibrosis, and found for example that the single nucleotide
polymorphism (SNP) of the interferon gamma receptor 2, a
pro-inflammatory gene known to be associated with pro-
gression to liver fibrosis in chronic hepatitis C patients, also
was related to liver stiffness in the Rotterdam Study par-
ticipants [231]. Recently, we found that coffee consump-
tion of three cups or more per day, which was found to be
beneficial in certain chronic liver diseases and liver fibrosis
[232], appeared associated with lower liver stiffness values
in the general population as well [233]. At this moment, we
are investigating differences in dietary composition
(macronutrients) and dietary patterns, body composition
and differences in gut microbiota between NAFLD and
non-NAFLD participants. Moreover, more studies are
currently underway to look at known and unknown genetic
and epigenetic factors for liver stiffness and NAFLD.
For additional EJE references please see [234, 235].
Neurological diseases
Objectives
Neuroepidemiologic research in the Rotterdam Study
focuses on the frequency, etiology and early recognition of
the most frequent neurologic diseases in the elderly. We
study neurodegenerative diseases (dementia, including
Alzheimer disease, and Parkinson disease), cerebrovascular
disease (both ischemic stroke and intracerebral hemorrhage
as well as transient ischemic attacks), migraine and
polyneuropathy. In all of these disorders clinical symptoms
typically become manifest late in the disease course, the
occurrence of clinical disease does not reflect the under-
lying spectrum of disease-related pathology, and most of
the clinical syndromes are etiologically heterogeneous.
Therefore, an additional research focus is on the causes and
consequences of pre-symptomatic (brain) pathology that
can be assessed with non-invasive modalities, which
include MR-imaging, cognitive testing, gait assessment,
and electromyography (EMG).
Major findings
In recent years, we have published contemporary data on
incidence of these major neurological diseases. We were
the first to show declining incidence of dementia [236] and
in recent papers we have demonstrated similar trends for
820 M. A. Ikram et al.
123
stroke [237] and Parkinson disease [238]. We have also
published on prevalence of polyneuropathy [239], showing
that 5.5% of the general population suffers from this dis-
ease with the disease going unrecognized in almost half of
these persons. We have also published normative data for
various pre-clinical markers, including cognition [240],
gait [241], and various MRI-markers [242–244].
One of the main areas of focus in recent years has been
understanding how brain pathology affects motor function,
with a special emphasis on gait. We have shown strong and
specific association of gait with cognition [245], DTI
markers [246] and daily functioning [247]. Ongoing work
regarding gait includes its longitudinal associations with
clinical diseases, including stroke, dementia and Parkin-
son’s disease. Interestingly, using a different test we have
already shown motor function to be a predictor of dementia
onset over a 9 year period [248]. Moreover, we have also
made several contributions towards understanding the eti-
ology of Parkinson’s disease [249–251].
Main findings in recent years with respect to stroke and
Alzheimer’s disease, include the study of the following
determinants: cerebral perfusion [252], thyroid function
[189], aortic valve calcification [253], white matter
microstructure [254], orthostatic hypotension [255], mid-
life blood pressure [256], depression [257], and parental
family history [258].
Similarly, we have now published on several determi-
nants of polyneuropathy [259, 260] and migraine [261]. In
coming years we will be seeking to develop a research line
on epilepsy.
Given our longstanding interest in unraveling the etiol-
ogy of neurodegenerative diseases, our current work also
involves leveraging the longitudinal and repeated data
collection from the Rotterdam Study to investigate trajec-
tories of various pre-clinical markers and disentangle the
patterns of how those relate to incident disease [262–264].
In the field of neurogenetics, we have contributed to or
led several conventional GWAS efforts as well as more
state-of-the-art genomics to discover novel genetic loci for
neurologic diseases and their endophenotypes [265–269].
Finally, we are actively investigating how findings on
etiology of neurologic diseases can be translated towards
public health issues on prevention [270, 271] as well as
clinical needs regarding prediction [254, 272, 273] and
possibly even interventional studies [274].
Methods update
Assessment of dementia and Alzheimer disease
In the baseline and follow-up examinations participants
undergo an initial screen for dementia with the Mini
Mental State Examination (MMSE) and the Geriatric
Mental Schedule (GMS), followed by an examination and
informant interview with the Cambridge Examination for
Mental Disorders of the Elderly (CAMDEX) in screen-
positives (MMSE\ 26 or GMS[ 0), and subsequent
neurological, neuropsychological and neuroimaging
examinations [275, 276]. Of subjects who cannot be
reexamined in person, information is obtained from the
GPs and the regional institute for outpatient mental health
care. A consensus panel makes the final diagnoses in
accordance with standard criteria (DSM-III-R criteria;
NINCDS-ADRDA; NINDS-AIREN).
Assessment of Parkinsonism and Parkinson disease
Participants are screened in the baseline and follow-up
examinations for cardinal signs of parkinsonism (resting
tremor, rigidity, bradykinesia, or impaired postural
reflexes). Persons with at least one sign present are
examined with the Unified Parkinson’s Disease Rating
Scale and a further neurologic exam. PD is diagnosed if
two or more cardinal signs are present in a subject not
taking antiparkinsonian drugs, or if at least one sign has
improved through medication, and when all causes of
secondary parkinsonism (dementia, use of neuroleptics,
cerebrovascular disease, multiple system atrophy, or pro-
gressive supranuclear palsy) can be excluded [277].
Assessment of stroke and stroke subtypes
History of stroke at baseline was assessed through inter-
view and verified in medical records. Putative incident
strokes get identified through the linkage of the study
database with files from general practitioners, the munici-
pality, and nursing home physicians’ files, after which
additional information (including brain imaging) is col-
lected from hospital records. A panel discusses all potential
strokes and subclassifies strokes into ischemic, hemor-
rhagic or unspecified [278, 279]. We also systematically
collect transient ischemic and neurological attacks [280].
Assessment of cognitive function
Global cognitive function is measured through the Mini
Mental State Examination (MMSE) in all surveys. From
the third survey (RS-I-3) onwards we added a 30 min test
battery that was designed to assess executive function and
memory function, and which includes a Stroop test, a
Letter Digit Substitution Task, a Word Fluency Test, and a
15 words Word List Learning test. This test battery was
expanded from the fourth survey onwards (RS-I-4) to
include motor function assessment using the Purdue Peg-
board Test. Moreover, from 2009 onwards we expanded
further by including the Design Orientation Test (DOT)
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and a modified version of the International Cooperative
Ataxia Rating Scale (ICARS), which assess visuo-spatial
orientation and ataxia respectively [240, 281, 282].
Assessment of gait patterns
Halfway through RS-III-1, we successfully implemented
the assessment of gait in all participants using the GAI-
TRite walkway (http://www.gaitrite.com/). Gait is assessed
using a 5.79 m long walkway (GAITRite Platinum; CIR
systems, Sparta, NJ, USA: 4.88 m active area; 120 Hertz
sampling rate) with pressure sensors. Participants perform
a standardized gait protocol consisting of three different
walking conditions: normal walk, turning and tandem
walk. In the normal walk, participants walk over the
walkway at their own pace. This walk is repeated four
times in both directions (yielding a total of 8 recordings).
In turning, participants walk over the walkway at their own
pace, turn halfway and return to the starting position (1
recording). In the tandem walk, participants walk tandem
(heel-to-toe) over a line visible on the walkway (1
recording). A total of 30 spatiotemporal gait variables are
calculated by the walkway software and downloaded off-
line for further analysis. Subsequently, principal compo-
nents analysis on these thirty gait variables is performed to
derive summarizing factors, referred to as gait domains.
The following gait domains are used: Rhythm, Pace, Pha-
ses, Base of Support, Variability, Tandem, and Turn. Gait
domains can be compared to cognitive domains, in which
each domain reflects a different aspect of the overall con-
cept [241]. Since 2 years we have added another walk to
our protocol, namely a dual-task walk, in which partici-
pants answer a difficult calculation, while walking over the
walkway. The aim of this walk is to compare it with the
original normal walk, thereby obtaining the amount of
central interference and input on gait.
Assessment of polyneuropathy
Starting in January 2013, we have successfully imple-
mented a protocol to assess polyneuropathy [239]. This
includes a full work-up including questionnaire, neuro-
logical exam, and EMG in all participants. In coming
years, we will publish on the prevalence, risk factors, and
clinical correlates of polyneuropathy in the general popu-
lation. The continuous measures of conductivity obtained
through EMG can also serve as excellent endophenotype
for genetic and biomarker studies.
Assessment of migraine
Migraine is assessed using a validated questionnaire and
includes information of aura, severity, and duration of
migraine [283].
Rotterdam Scan Study: brain imaging within the Rotterdam
Study
In 1991, a random sample of 111 participants underwent
axial T2-weighted magnetic resonance (MR) imaging to
assess presence and severity of white matter lesions [284].
In 1995, a random sample of 563 non-demented partici-
pants underwent brain MR imaging in the context of the
Rotterdam Scan Study. From August 2005 onwards (RS-II-
2 and further), a dedicated 1.5 Tesla scanner is operational
in the research center of the Rotterdam Study, and brain
imaging is performed in all study participants without
contra-indications [285].
Currently, the follow-up of this latter sample extends to
up to 12 years (see further section on population imaging).
For additional EJE references please see
[273, 286–303].
Ophthalmic diseases
Objectives
Ophthalmic research in the Rotterdam Study focusses on
occurrence, causally related determinants, and predictors of
common eye diseases. Our main focus is on age-related
macular degeneration (AMD), glaucoma, and myopia, and
particularly in the last few years we investigated genetic
risk variants and pathways. To this end, we connected with
many other epidemiologic studies in all parts of the world
and formed large international consortia.
Major findings
Age-related macular degeneration (AMD)
AMD has been genetically dissected for the most part, and
the past 2 years were geared towards understanding the
genetic effects and their role in AMD pathogenesis. With
the IAMDGC consortium, we analyzed 33,000 participants
and identified 52 independently associated common and
rare variants distributed across 34 loci [304]. Many of these
loci harbored novel genes, and aside from many common
variants, various rare variants were identified. The genes in
the complement cascade as well as ARMS2 remained the
major genes. A subsequent exercise of IAMDGC was to
evaluate pleiotropy of the AMD risk variants, and it was
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found that at least 16 disorders show substantial genetic
overlap with AMD [305]. In our own Rotterdam cohort, we
used the findings from IAMDGC to investigate genetic
variants in miRNAs and miRNA-binding sites [306]. We
identified variants in miRNAs (miR-4513; miR-3591; miR-
3135b), and 54 variants in miRNA-binding sites associated
with AMD. Experimentally, we showed that miR-210-5p
influences expression of CFB. These findings are exciting
as they point to potential targets that can control the
complement pathway, and halt AMD progression. Apart
from genetics, we also studied phenotypic association and
course of disease. Together with two other population-
based studies (3CC), we found that 19–28% of unilateral
any AMD became bilateral in 5 years, and 27–68% of
unilateral late AMD became bilateral during that time
[307]. Smoking and carriership of genetic risk variants
increased progression rates substantially. We also investi-
gated retinal pseudodrusen in more detail, a distinct AMD
lesion [308]. 5% of the Rotterdam Study had these lesions,
women twice as often as men, as did carriers of certain
genotypes.
Myopia (nearsightedness)
We prolonged our research in the field of refractive errors
and myopia in the CREAM consortium.
This time we performed a joint meta-analysis to test
gene-environment interaction effects, and identified six
novel loci (FAM150B-ACP1, LINC00340, FBN1, DIS3L-
MAP2K1, ARID2-SNAT1 and SLC14A2) associated with
refractive error [309]. In Asian populations, three genome-
wide significant loci AREG, GABRR1 and PDE10A also
exhibited strong interactions with education. These find-
ings clearly show that genes for refractive errors need
environmental triggers in order to have a significant effect.
We were also interested in the susceptibility period for
refractive error genes. We therefore investigated the asso-
ciation between age-of-onset of variants at our previously
identified loci and refractive error in various cohorts of
different ages, including the Rotterdam Study [310].
Specific variants could be categorized as showing evidence
of: (a) early-onset effects remaining stable through child-
hood, (b) early-onset effects that progressed further with
increasing age, or (c) onset later in childhood. This shows
that most genes in a complex trait such as refractive error
do not have a continuous effect, but rather act during a
specific age period. Next steps in myopia research will
include gene finding in very large data sets ([ 100,000),
identification of pathways, and search for leads for
intervention.
Primary open-angle glaucoma (POAG)
The glaucoma research entailed gene finding as well as the
study of the associations with glaucoma parameters. The
latter included the study of intraocular pressure (IOP)
across Europe in the E3 (N = 43,500) consortium [311].
Higher IOP was observed in men, with higher body mass
index, shorter height, higher systolic blood pressure, and
more myopic refraction. An inverted U-shaped trend was
observed between age and IOP, with IOP increasing up to
the age of 60 and decreasing in participants older than
70 years. Gene finding was performed in the IGGC con-
sortium. We conducted a genome-wide association meta-
analysis of IOP and optic disc parameters and validated our
findings in multiple sets of POAG cases and controls. We
identified 9 new loci for vertical cup-disc ratio (VCDR), 1
for IOP, 5 for optic nerve cup area, and 6 for disc area.
Some genomic regions affected both IOP and the disc
parameters. Furthermore, we identified a novel association
between CDKN1A and POAG, statistically as well as
functionally in a zebrafish model. We also evaluated
sequence variations in the myocilin (MYOC) gene, a gene
that accounts for approximately 2–4% of glaucoma cases
[312]. Mutation Gln368Stop in this gene is known to
increase intraocular pressure. We found that this variant
was also very frequent among unaffecteds from The
TwinsUK and Rotterdam Study (12.5 and 19.4%, respec-
tively). This showed that this seemingly functional variant
may not have such large effects as previously thought.
Finally, we investigated the performance of a new refer-
ence panel, the Haplotype Reference Consortium (HRC),
for imputation of genetic variants [313]. We showed that
imputation using the HRC panel improved the concordance
between assayed and imputed genotypes at common, and
especially, low-frequency variants. HRC imputation sig-
nificantly improved P values for genetic associations with
glaucoma parameters, thus our next step is to continue gene
discovery using HRC in very large data sets of multi-ethnic
origin.
Retinal vasculature
We also continued this line of research and investigated the
meaning of vessel diameter in the retina for pathology at
other parts of the body, in particular the brain [314–318].
Retinal vessel calibers were associated with enlarged
perivascular spaces in the brain and with white matter
microstructure. Interestingly, it was also associated with
survival, vitamin D, and N-Terminal Pro-B-Type Natri-
uretic Peptide, a protein associated with ischemia. This
indicates that retinal vessel diameters are important
biomarkers for the vascular status elsewhere in the body,
and may predict life expectancy.
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Methods update
At baseline and follow-up examinations, participants
undergo ophthalmic measurements including best-cor-
rected ETDRS visual acuity, refractive error, Goldmann
applanation tonometry, keratometry, slit lamp examination
of the anterior segment, and visual field testing. After
pharmacological mydriasis, we make 35 color pho-
tographs of the macular area, and 20 simultaneous
stereoscopic imaging of the optic disc and macular area
using stereoscopic digital imaging (Topcon camera). We
image retinal layers at the macula and optic disc with
Fourier3D Spectral domain optical coherence tomography
(Topcon), measure axial length, and biometry of the cor-
nea, anterior chamber, lens, posterior chamber, and retina
with Lenstar (Haag-Streit); and perform fundus autofluo-
rescence, infra-red and red-free measurements with Hei-
delberg. For the newest cohort (RS4-1), we have added
corneal topography measurements (Pentacam; Oculus), and
replaced visual field screening by Frequency Doubling
Technology C20-2 (Carl Zeiss Meditec). The classification
of AMD, POAG, refractive error, and retinal vessel
diameters remain unchanged.
For additional EJE references see [311, 319–322].
Psychiatric epidemiology
Objectives
The aim of the psychiatric research in the Rotterdam Study
is to investigate the determinants, correlates and conse-
quences of common psychiatric problems in the elderly.
The focus lies on studies of depressive and anxiety disor-
ders, sleep disturbances, and complicated grief.
Study design update
Since 1994 (RS-I-2) most participants in the Rotterdam
Study are screened for depressive symptoms and from the
third examination (RS-I-3), 1997–1999, onwards, depres-
sive disorders have been ascertained systematically.
Assessments of anxiety disorders, sleeping disturbances,
and complicated grief were added in the subsequent
examination (RS-I-4) and have been performed in all fol-
low-up visits of the original and added cohorts. Other
additions to the protocol included a screening for psychotic
symptoms in one cohort (RS-III) and, from January 2012 to
October 2014, ambulatory polysomnography. In a sub-
sample, taedium vitae was assessed. The most recently
introduced assessments include sexual activity, aggression
and neuroticism.
Major determinants
Psychiatric research in the Rotterdam Study focuses on
biological risk factors. The vascular depression hypothesis
was tested with different measures of atherosclerosis,
arterial stiffness and cerebral blood flow [323]. We
examined whether blood levels of vitamins and fatty acids,
immune parameters, and markers of folate metabolism
increased the likelihood of depression [324]. Diurnal pat-
terns of cortisol secretion were studied and recently we
performed a low-dose dexamethasone test to assess the
negative feedback of the hypothalamic–pituitary–adrenal
(HPA) axis functioning [325]. Moreover, several GWAs
were conducted in collaborative efforts focussing on
depressive symptoms, sleep, anxiety and cortisol
[326–328]. Several, mostly cross-sectional studies of brain
morphology as possible determinants and correlates of
common psychiatric disorders were completed [329]. Also,
psychiatric problems and psychological traits such as
happiness, sleep duration, and depression are increasingly
investigated as determinants of health and mortality
[330, 331].
Major clinical outcomes
Information on depression is obtained from (a) psychiatric
examinations, (b) self-reported histories of depression,
(c) medical records, and (d) registration of antidepressant
use [332]. The psychiatric examination during each visit
consists of an assessment and screening with the Center for
Epidemiologic Studies Depression Scale (CES-D), and in
the screen-positive participants a semi-structured interview
performed by a trained clinician (Schedules for Clinical
Assessment in Neuropsychiatry). To continuously monitor
incidence of depression throughout follow-up, trained
research-assistants scrutinize the medical records of gen-
eral practitioners and copy all information mentioning
depressive symptoms.
The following anxiety disorders are assessed with a
slightly adapted Munich version of the Composite Inter-
national Diagnostic Interview: generalized anxiety disor-
der, specific and social phobia, agoraphobia without panic
disorder, and panic disorder [333]. In addition, the HADS-
A is used to assess anxiety traits continuously.
Sleep quality and disturbance is measured with the
Pittsburgh Sleep Quality Index. In addition, sleep duration
and fragmentation are assessed with actigraphy, a method
that infers wakefulness and sleep from the presence or
absence of limb movement [334]. In total, nearly 2000
persons participated in this actigraphy study: they wore an
actigraph and kept a sleep diary for, on average, six con-
secutive nights. Follow-up assessments of actigraphic
assessments in these participants have been conducted.
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Ambulatory polysomnographic (PSG, i.e., full sleep EEG)
recordings of one night have been conducted in 940 par-
ticipants. We scheduled home visits of a research assistant
who placed the sensors to record an ambulant PSG (Vita-
port 4; Temec, Kerkrade, the Netherlands). The PSG
included six EEG channels, bilateral electrooculography,
electromyography, electrocardiography, respiratory belts
on the chest and abdomen, oximetry, and a nasal pressure
transducer and oronasal thermocouple to measure airflow
[335]. All recordings were scored according to American
Association of Sleep Medicine guidelines by a registered
Sleep Technologist. Recordings were manually scored in
30- s epochs for identification of sleep stages; each epoch
was scored as Wake, N1, N2, N3 or REM sleep. In addi-
tion, we used PRANA (PhiTools, Strasbourg, France)
software to automatically measure the microstructure of
sleep, e.g. spindles and REM density. Polysomnography
recordings are also used to calculate the apnea–hypopnea
index.
Circadian rhythms: Sleep–wake activity patterns over a
week are studied with actigraphy As a marker of circadian
rhythms. In more than 1700 persons we calculated inter-
daily stability, i.e. the stability of the rhythm over days and
the intra-daily variability, i.e. the fragmentation of the
rhythm [336].
The Inventory of Complicated Grief is used to identify
traumatic grief. This is a condition distinct from normal
grief and bereavement-related depression, characterized by
symptoms like disbelief about the death and searching for
the deceased.
Major findings
Depression In a series of studies we found some evidence
for the vascular depression hypothesis. More severe coro-
nary and extra-coronary atherosclerosis were associated
with a higher prevalence of depression, as were cerebral
haemodynamic changes [323]. However, our data did not
support a specific symptom profile of vascular depression
as previously defined. Most importantly, we found no
longitudinal relation between peripheral atherosclerosis
and incident depression [337]. Recently, we prospectively
studied cerebral vascular risk factors such as white matter
lesions, silent infarcts or blood flow in relation to depres-
sion [338]. We found evidence that small vessel disease
predicted the onset of depression. This suggests that
atherosclerotic processes in the brain are a specific risk
factor for depression.
Sleep We investigated the relationships of sleep duration
with both cardiovascular risk factors and psychiatric dis-
orders. We also aimed to explain sex differences in sub-
jective and actigraphic sleep parameters [339]. If assessed
by diary or interview, elderly women consistently reported
shorter and poorer sleep than elderly men. In contrast,
actigraphic sleep measures showed shorter and poorer sleep
in men. These discrepancies were partly explained by sleep
medication use and alcohol consumption. The first results
using polysomnography to measure sleep EEG suggest that
REM-density is a marker of depressive symptoms in the
general population [335]. Other results suggest that sleep
apnea and depressive symptoms are not related, although
both result in fatigue [340].
Anxiety We studied anxiety as a determinant of mor-
tality and cardiovascular disease, and found anxiety in the
elderly does not predict physical morbidity independent of
baseline health and behaviour. In contrast [341], we could
show that mild cognitive impairment is associated with
incident anxiety disorders [342].
Complicated grief In our population-based study of
5741 elderly persons, current grief was reported by 1089
participants, of these 277 (25 or 4.8% of total) were
diagnosed with complicated grief, the vast majority of
which had no clinical symptoms of anxiety or depression.
Persons with complicated grief were older, had a lower
level of education, and more often had lost a child [343].
Recently published work suggests that complicated grief
occurs together with structural brain atrophy more often
than expected by chance [344].
Sexual activity Almost half of partnered older adults
engage in sexual activity and over two-thirds engage in
physical tenderness, but very few unpartnered older adults
engage in sexual behaviour [345]. The greatest barrier to
being sexually active at older age is lack of sexual partner
availability, for which women are particularly disadvan-
taged. Moreover, sexual activity is strongly determined by
well-being, in particular happiness rather than lack of
depression [346].
Genetics of common psychiatric disorders In the past
years, we have performed a series of genome-wide asso-
ciation studies of the above psychiatric and psychological
phenotypes, mostly as part of the CHARGE consortium
and more recently as part of the Psychiatric Genetics
Consortium. While initial analyses yielded no convincing
genome wide significant results as studies were strongly
underpowered, more recent work with larger sample sizes
led by our group in the CHARGE or as part of the PGC
consortium shows promising results for depression and
depressive symptoms [326].
Finally, ongoing psychiatric research projects examine
whether and how psychological well-being or psychiatric
problems contribute to survival. Most importantly, we are
interested in whether the effects are specific to certain
behaviour or emotions, are independent of confounding by
physical disease, or can be explained by lifestyle,
immunological or hormonal regulation [347].
For additional EJE references see [348–353].
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Respiratory diseases
In the Rotterdam Study (RS) we investigate the prevalence
and incidence of respiratory diseases in middle-aged and
older adults, and aim to elucidate the genetic, environ-
mental and life style risk factors for the occurrence of these
diseases. Moreover, by applying systems genetic and sys-
tems biology approaches, we aim to decipher the patho-
genesis and pathophysiology of respiratory diseases. The
main focus of research of the respiratory epidemiology
group is on common obstructive airway diseases, encom-
passing asthma, ACOS (Asthma COPD Overlap Syn-
drome) and Chronic Obstructive Pulmonary Disease
(COPD), but also respiratory infections, pneumonia, pul-
monary hypertension and lung cancer are thoroughly
investigated. Lung function measurements encompassing
spirometry and diffusion capacity are performed in all
participants during the research centre visit of the RS using
a Master Screen PFT Pro by trained paramedical per-
sonnel according to ERS/ATS Guidelines [5, 354].
Lung function and Chronic Obstructive Pulmonary
Disease (COPD)
In the large prospective population-based RS cohort, we
have determined the prevalence and incidence of COPD in
older adults according to age, sex and smoking history
[355, 356]. In international collaboration, we have eluci-
dated the genetic determinants of the lung function mea-
surements Forced Expiratory Volume in one second
(FEV1), Forced Vital Capacity (FVC) and the FEV1/FVC
ratio, the defining characteristic of an obstructive syndrome
[357–360]. In the most recent genome-wide association
study of COPD, we have discovered 22 loci of genetic
susceptibility, including 9 loci which have been previously
associated with lung function in the general population, and
4 new loci (EEFSEC, DSP, MTCL1 and SFTPD) [359].
Intriguingly, we highlighted that 2 loci associated with
COPD (FAM13A and DSP) were shared with pulmonary
fibrosis, but had opposite risk alleles. Moreover, using a
systems genetics analysis approach, we have discovered
the molecular mechanisms underlying variations in lung
function [361].
COPD, co-morbidities and frailty
COPD does not only affect the lungs, but is frequently
associated with extrapulmonary manifestations and sys-
temic consequences. Therefore, we have investigated
multiple co-morbidities of COPD, encompassing cardio-
vascular diseases, cerebrovascular diseases (Carotid artery
atherosclerotic plaques, cerebral microbleeds and stroke)
and osteoporosis [362–367]. Importantly, we have metic-
ulously validated acute exacerbations of COPD in partici-
pants with COPD in the RS, and examined the impact of
these exacerbations on acute cardiovascular events (e.g.
atrial fibrillation, sudden cardiac death), acute cere-
brovascular events (stroke), and mortality [367, 368].
Moreover, we have highlighted differences in the distri-
bution of cause-specific mortality in patients with COPD
according to disease stage [363, 366].
Frailty is a common geriatric syndrome, characterized
by a lack of functional reserve to stressors, and defined by
Fried et al. as meeting three or more of five established
criteria for frailty (nutritional status, physical activity,
mobility, grip strength and exhaustion). Of 2833 RS par-
ticipants with sufficiently evaluated frailty criteria, 163
(5.8%) participants were frail, whereas the prevalence of
frailty was significantly higher in subjects with COPD
(10.2%) [369]. Adjusted for age, sex and co-morbidities,
frail elderly had a significantly increased risk of dying
within 3 years, compared to the non-frail elderly [370]. In
subjects with COPD, the prevalence of frailty was highest
when they suffered from severe airflow limitation, dyspnea
and/or frequent exacerbations. Importantly, COPD elderly
who were frail had significantly worse survival [369].
Therefore, COPD is a key component of the chronic dis-
ease domain of the Healthy Aging Score, which has
recently been developed by the RS investigators [35].
Additional EJE references see [356, 371–374].
Genomics, biomarker and microbiome studies
Objectives
The team in this research line focusses on bio-banking
activities of the participants of the Rotterdam Study and
investigates molecular biological determinants of disease
in these specimen (i.e., DNA, RNA, proteins, metabolites,
microbes, etc.). Bio-banking involves collecting, storing
and managing the biological tissues of participants of the
Rotterdam Study at all follow-up measurements. This
concerns mainly blood, urine, saliva, hair and faeces but
with microbiome studies several other specimens are being
collected (such as skin swaps, nose swaps, eye swaps, etc.).
We have further stored PBMC’s for the isolation of
induced pluripotent stem (iPS) cells. The research focus of
this group concerns assessment of biological determinants
of disease (biomarkers) in these biomaterials and the
analysis of markers using genomic technologies (such as
SNP arrays and next generation sequencing (NGS)). The
materials and data generated by this research line now sum
up to * 3 9 1012 data-points, and are actively used by all
research groups of the Rotterdam Study. An overview of all
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the ‘‘omics’’ datasets in the Rotterdam Study cohorts is
given in Table 1.
Major findings
Rotterdam Study investigators are playing leading roles in
several of the large global consortia focused on assessing
the contribution of complex disease gene variants by
prospective meta-analysis across many epidemiological
cohorts, such as in CHARGE and ENGAGE, and in many
disease/phenotype focused efforts such as ADSP, IGAP,
PERADES, GIANT, GEFOS, REPROGEN, TREATOA,
DIAGRAM, etc. Since 2005 the genome wide association
study (GWAS) has changed the field of complex genetics,
and identified a still growing list of thousands of common
genetic variants contributing to disease risk. While this
large scale global collaboration has originated from the
GWAS era, similar consortia have been built around the
genomics datasets with RNA expression profiles, DNA
methylation profiles, and the NGS datasets on DNA, RNA
and microbiomes, including the BBMRI-NL sponsored
BIOS consortium and several CHARGE working groups.
The Rotterdam Study has GWAS data for almost the
complete dataset summing to * 12,000 DNA samples,
and is involved as a major collaborative center for meta-
analysis studies of GWAS data, including national pro-
grams (BBMRI-exome chip, BBMRI-BIOS), and interna-
tional consortia (see above). Especially, from the
CHARGE consortium many important publications have
emerged on a wide variety of phenotypes and diseases from
all major research lines in the Rotterdam Study. They are
discussed under the subheadings of each individual
research line.
Data collection, storage and management
In the RS-III round, the collection of faeces material has
been initiated for the intestinal microbiome analysis. For
this a collection pot is distributed at the research center
visit which is to be used at home and then returned by
postal mail to Erasmus MC where DNA is isolated and
stored at - 80 C. This has been done for * 2000 samples
in RS-III, and is now continuing for the whole RS study
population (with the modification that participants bring
their sample directly to the research center to be stored at
- 80 C) following the cycles of visits to the research
center, including longitudinal visits.
Table 1 Overview of sample
numbers with ‘‘omics’’ datasets
across the 3 Rotterdam Study
(RS) cohorts with the number
and type of measurement for
each omic method
Genomics data type Total Datapoints/sample RS Ia RS IIa RS IIIa
Number Type
GWAS SNP data 11,502 40,000,000 SNPs 6291 2157 3054
Exome array 3183 250,000 SNPs 3183 – –
Whole exome sequencing (WES) 3778 693,000 Variants 3778 – –
Whole genome sequencing (WGS) 96 3,000,000 Variants 96 – –
Genome wide expression (array) 881 25,000 Genes – – 881
Genome wide expression (RNA Seq) 829 18,000,000 Reads – 500 329
Genome wide DNA methylation 1600 450,000 CpG’s 100 500 1000
Telomere length (PCR) 1800 1 – 1800 – –
Mitochondrial DNA (PCR) 500 1 – 500 – –
Microbiome 16S rRNA (faeces) 2000 500 OTU’s – – 2000
Metabolomics (NMR/UPLC MS) 1826 4000 Metabolites 1826 – –
Metabolomics (NMR ‘‘Nightingale’’) 5381 228 Metabolites 2880 663 1838
Serum protein profileb 9820 35 Proteins 3812 2542 3466
Total ‘omic’ datapoints in RS: 43,196 9 62,422,765 = 2,696,413,756,940
SNP single nucleotide polymorphism, CpG a two-nucleotide position (C next to G on the same strand) of
which the C can be methylated; OTU operational taxonomic unit
aRS1, First cohort of the Rotterdam Study; RS2, Second cohort of the Rotterdam Study; RS3, Third cohort
of the Rotterdam Study
bTotal estradiol, total testosterone, sex hormone-binding globulin, dehydroepiandrosterone, dehy-
droepiandrosterone sulfate, androstenedione, 17-hydroxyprogesterone, cortisol, corticosterone, 11-des-
oxycortisol, vitamin D, thyroid stimulating hormone, free T4, interleukins, C-reactive protein, Insulin-like
growth factor 1, insulin, iron, ferritin, transferrin, fibrinogen, homocysteine, folic acid, riboflavine, pyri-
doxine, SAM/SAH ratio, cobalamine, Lp-PLA2, Fas/Fas-L, abeta42/40
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Metabolomics
Two datasets have been created in the Rotterdam Study
sub-cohorts that contain information on metabolomics in
blood serum or plasma of participants.
A. As part of the COMBI-BIO consortium, we used large-
scale untargeted serum metabolic profiling by proton (1H)
nuclear magnetic resonance (NMR) spectroscopy and
UPLC Mass Spectrometry to characterize the metabolic
signature of 1826 individuals from RS-I-3 in relation with
vascular health and cardiovascular disease.
B. High-throughput metabolomics measurements as a part
of the Biobanking and BioMolecular resources Research
Infrastructure The Netherlands (BBMRI-NL) initiative
have been performed using plasma samples which were
collected in EDTA coated tubes. Fasting samples from
RS-I (n = 2880), RSII (n = 663), and RS-III (n = 1838)
cohorts have been specifically selected in order to
maximize the analytical number of prospective gene
expression and gut microbiome research in relation to
metabolomics. The plasma samples analyzed by the
biomarker platform of Nightingale Health using proton
nuclear magnetic resonance (NMR) technique. Spectra
have been obtained from 600 to 500 MHz instruments,
using three molecular windows, namely lipoproteins,
lipids and low molecular weight compounds. The spectra
were then de-convoluted by Nightingale’s proprietary
bioinformatics software leading to quantification of
absolute concentrations. The yielding biomarker data
contains 228 measurements on apolipoproteins, lipopro-
teins sub-classes, amino acids, albumin, glucose, glycol-
ysis metabolites, ketone bodies, glycoprotein,
sphingolipid, phosphoglyceride, polyunsaturated fatty
acids and cholesterols [375].
The Human Genomics facility (HuGe-F)
The Rotterdam Study uses the Human Genotyping Facility,
HuGE-F (www.glimdna.nl) for all its genomic studies, and
which has been generating all GWAS data for the Rotter-
dam Study as well as its RNA expression profiles, DNA
methylation profiles, and all NGS data including whole
exome sequences (WES), RNA sequencing data, and the
microbiome 16S ribosomal RNA (rRNA) sequencing data.
Genome-wide association studies (GWAS) datasets
The GWAS dataset of * 12,000 DNA samples from the
Rotterdam Study RS-I, -II-, -III cohorts consists of a) a
small dataset of * 400 women with 500 K Affymetrix
arrays (Nsp250 ? Sty250; the so-called ‘‘pilot’’ dataset),
and b) a large dataset of * 12,000 samples consisting of
550 K (RS-I, II; single ? duo array format) and 610 K
(RS-III; quattro array format) Illumina array genotypes. In
the pilot dataset also other array types have been run such
as the Illumina Omniexpress 2.5 array, and the new Illu-
mina GSA array and the Affymetrix PMRA array allowing
for comparisons.
The Illumina GWAS genotype datasets of the Rotterdam
Study also form the basis to generate so-called ‘‘imputed’’
datasets derived thereof. In this process the genotypes of
SNPs which have been genotyped in reference datasets
(such as HapMap with * 2.5 million SNPs genotyped or
HRC with 40 million SNPs), are being estimated for all
Rotterdam Study samples using the basis Illumina 500 K
SNP dataset configurations in each subject. With the advent
of large reference datasets becoming available based on
whole genome/exome NGS, imputation activities using the
Rotterdam Study (RS) GWAS dataset will remain an active
area of development. So far, the RS GWAS datasets have
been imputed to HapMap version 2 and 3 (with * 2.5
million resulting imputed SNP genotypes obtained for the
RS dataset), the 1000 genome (1 KG) dataset version Iv3
and IIIv5 (with * 30 and 50 million resulting SNP geno-
types, respectively), the Genome of the Netherlands
(GoNL), the UK10 k whole genome sequencing dataset,
and, more recently, the haplotype reference consortium
(HRC) r1.1 dataset (* 40 million SNPs). Especially the
latter imputation uses as a reference up to 64,976 haplo-
types allowing also the study of less frequent to rare
variants and comprising 40 million SNPs, all with an
estimated allele count greater than 5.
Candidate gene SNPs and special genomic markers
About 300 SNPs in several candidate genes have been
individually measured over the past 15 years, (including
genes such as ApoE, VDR, ESR1, fibrinogen, etc.). Addi-
tionally, for a subset of RS-I samples telomere length
(n * 1800) and mitochondrial DNA content (n * 500)
was measured.
Next generation sequencing datasets
Whole genome sequencing (WGS) dataset
The whole genome sequencing dataset consists of 100
samples in RS-I which were sequenced as part of the
Genome of the Netherlands (GoNL) [376], with an average
sequencing depth of 69 and with improved phasing
because of the trio-design.
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Whole exome sequencing (WES) datasets
WES NGS data in RS-I is available for 2628 samples as
part of the NCHA sponsored project and were generated by
the HuGe-F facility on the Illumina HiSeq2000 sequencing
machines. The samples for this experiment were selected to
constitute a random sample from the RS-I dataset. Through
a collaborative grant from the NIH Alzheimer initiative
(ADSP) we have obtained an additional * 1.20 samples
with WES NGS data from RS-I generated at the Broad
Institute, Boston, USA, of which 50 overlap with the
NCHA WES dataset)so net total samples with WES data is
3778). The Rotterdam Study WES dataset is now also part
of the so-called commons dataset of the CHARGE con-
sortium with * 16,000 WES samples and 5000 WGS
samples.
RNA sequencing dataset
BBMRI has sponsored a collaborative effort to create a
large-scale data infrastructure to work on integrative omics
studies in Dutch Biobanks. For this the Erasmus MC
HuGe-F genomics facility has generated RNA sequencing
profiles of in total ± 4000 individuals of six Dutch bio-
banks, including the Rotterdam Study. A total number of
900 RS-samples were RNA-sequenced at a depth of 30
million paired end reads. Together with colleagues at
UMCG Groningen and LUMC Leiden, the dataset was QC-
ed and annotated RNA-expression profiles were generated,
and relations between genetics, transcriptomics, and epi-
genetic measures have been analyzed (see below) and is
freely available for all researchers (http://www.bbmri.nl/
on__offer/bios/).
New developments
Incidental findings in WES data
Based on the RS WES dataset and the exome chip dataset
we have initiated to look for so-called incidental findings
which might be clinically relevant. This is done by deter-
mining presence of variants in particular sets of genes such
as the list of 57 ‘‘actionable’’ genes as established by the
American College of Medical Geneticists (AMCG). This
research is ongoing, we have established a working group
together with Dr Chris O’Donnell, and this is done in
collaboration with several groups such as the Broad Insti-
tute (Drs. Eric Minikel, Daniel MacArthur) and University
of Cologne (Prof. Hilger Ropers). A first result showed that
carriers of supposedly pathogenic mutations in the prion
gene did not display an evident disease phenotype [377].
WES data was also used to investigate the association
between all-cause mortality and carrier-status of somatic
mutations in genes linked to clonal expansion of
hematopoietic stem cells. We found that, unlike previous
reports in predominantly middle-aged individuals, somatic
mutations in genes linked to clonal expansion of
hematopoietic stem cells do not compromise the 8- to
10-year survival in the oldest old [378].
Integrative genomics
Within the Rotterdam Study subcohorts, epigenetic, tran-
scriptomic and microbiome datasets have been generated.
Using this data, context-dependent expression quantitative
trait loci (eQTL) were identified [379]. In addition, it was
found that disease associated genetic variants (GWAS hits)
alter transcription factor levels and methylation of their
binding sites, offering true biological insight into mecha-
nisms behind the associated GWAS hits [380].
The epigenetic and transcriptomic data have increas-
ingly been explored for associations with disease and traits,
and especially environmental factors. Unlike previous
efforts in using transcriptomic datasets, this is now also
done in large collaborative efforts, increasing robustness
and value of the results. Methylation signatures were
identified for smoking [62, 381], alcohol consumption
[382], low grade inflammation [383], liver enzymes and
hepatic steatosis [384], lipids [106], body mass and the
adverse outcomes of adiposity [385].
Similarly, transcriptomic profiles were identified for
smoking [386], fasting glucose and insulin levels [387] and
muscle strength [210]. The first epigenome-wide study was
also attempted in relation to bone mineral density variation
[388].
A number of studies have focused on the relationship
between diverse molecular layers and (biological) aging. A
large gene expression meta-analysis in 14,983 individuals
identify 1497 genes that are differentially expressed with
chronological age. The gene expression profiles were used
to calculate the ‘transcriptomic age’ of an individual; dif-
ferences between transcriptomic age and chronological age
were associated with biological features linked to ageing
[389]. In a meta-analysis of 3089 individuals were
methylation levels were used as a biomarker for ‘‘biolog-
ical age’’, often referred to as ‘‘epigenetic age’’, it was
shown that epigenetic age predicts all-cause mortality
above and beyond chronological age and traditional risk
factors [390].
Furthermore, we showed that blood RNA expression
profiles undergo major changes during the seventh decade
of life [391]. It was shown to be feasible to accurately
estimate human age from blood using information from
different molecular layers [392].
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Microbiome 16S NGS dataset
HuGe-F has optimized and applied stool/faeces collection
protocols and used 16S sequencing protocols (NGS of the
16S rRNA v3/v4 area) to characterize the gut/intestinal
microbiome. We have collected * 2000 stool samples in
the RS-III sub-cohort from which DNA has been isolated
and which have been sequenced on 16S v3/v4 by NGS on
Illumina MiSeq sequencing machines. For other sources of
microbiomes (eye, urine, mouth, skin, etc.) several pilot
projects have shown their feasibility while sampling and
sequencing protocols were optimized (e.g., for some
microbiome body niches other 16S areas need to be
sequenced). For all these other body niches larger sampling
efforts are now ongoing in the ongoing collection rounds of
the Rotterdam Study. These can be found under the
description of the respective research lines.
Reproductive traits
Objective
The main objective of this program is to study frequency
and etiology of major disorders of the reproductive system
and their risk factors, including age-at-menopause and
fertility. Since most analyses involve women, this program
is centered around the study of women’s reproductive
health. The evaluation of risk factors includes serum
measurements of hormones as well as genetic and genomic
determinants of reproductive health and related diseases,
and studies of the sex chromosomes X and Y. In addition,
consequences of these conditions are studied in relation to
other aging-related diseases, including cardiovascular dis-
ease and disorders of the locomotor system.
Major GWAS findings
Much of the work of this research is made possible by
large-scale collaboration in consortia, some of which focus
on one particular disease or trait while others are more
broad spectrum strategic collaborations. We are part of
several such large consortia studying genetic and epi-
demiological risk factors for reproductive traits such as
CHARGE, REPROGEN, SSCAG and PCOSGEN.
Most attention so far has gone to the study of age-at
natural-menopause (ANM) and age-at-menarche in women
for which our group was the first to report the major loci for
age-at-menopause [393, 394]. Many of these signals were
also observed for women of other ancestries [395] although
the studies of other ethnicities are smaller and thus lack in
power. In the most recent and largest meta-analysis of
GWAS of age-at-menopause so far [396], 44 loci were
identified among 70,000 women, of which two with rare
variants with large effect size (HELB and SLCO4A1) as
discovered by exome-array-based meta-analysis. Together,
the genome-wide significant variants explain * 6% of the
genetic variation which went up to 21% if we take all SNPs
with P\ 0.05.
In Mendelian Randomization studies a causal effect was
established for age at natural menopause as a risk factor for
breast cancer (but not prostate cancer in men), while the
effect size was greater for ER-positive than ER-negative
breast cancers [396, 397]. Similar MR studies are now
ongoing for other common diseases influenced by age-at
menopause such as cardiovascular disease and
osteoporosis.
Interestingly, the majority of the loci determining age-
at-natural menopause involve genes which are important in
the DNA damage response and DNA repair pathways
which points to the importance of this system in main-
taining an error-free stem cell lineage which produce the
oocyte. As such the phenotype of age-at-menopause, rep-
resents an interesting model for age-related changes in cell
function maintenance and functions as a model to identify
molecular mechanisms for damage accumulation and
repair during ageing [398].
Several diseases related to infertility, such as Early
menopause (EM)/Primary Ovarian Insufficiency (POI) and
PolyCystic Ovary Syndrome (PCOS) are now subjected to
GWAS and look ups with ANM SNPs. In a GWAS of 3493
EM cases and 13 598 controls from 10 independent studies
[399], no novel genetic variants were discovered, but the
17 variants previously associated with normal age at nat-
ural menopause as a quantitative trait were also associated
with EM and primary ovarian insufficiency (POI). In a
GWAS of PCOS in 5184 self-reported cases and 82,759
controls [400], 6 loci were identified in/near genes ERBB4/
HER4, YAP1, THADA, FSHB, RAD50 and KRR1. MR
analyses in this study identified causal roles in PCOS
aetiology for higher BMI, higher insulin resistance, later
menopause, and lower serum SHBG.
For several endocrine biomarkers GWAS have been
performed to identify the genetic loci influencing their
serum levels, i.e., testosteron [401], SHBG [402], DHEAS
[403], and these are also involved in several MR analyses
in relation to major disease endpoints for which these
biomarkers have been suggested to be predictive.
In a collaboration with the SSCAG consortium, a recent
GWAS of human fertility characteristics (defined as age at
first new born (AFB) and number of children ever born
(NEB)) in both sexes including 251,151 individuals for
AFB and 343,072 individuals for NEB, identified 12 loci
[404]. While none of the AFB- or NEB-associated SNPs
are associated with age at menopause, there was some
overlap with SNPs for behavioral and reproductive
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phenotypes (such as educational attainment, age-at-me-
narche, bmi, and age at first sexual intercourse).
Methods update
Several specific biomarker assessments in * 10,000
blood/serum/plasma and urine samples have been done for
the diagnosis and evaluation of risk factors of reproductive
traits (e.g., steroid hormones; see under ‘‘genomics,
biomarkers, and microbiome’’). Current work involves
analyses of X and Y chromosome mosaicisms as can be
detected in genomic DNA extracted from blood, and how
these mosaicisms change with ageing. In addition, DNA
methylation is analyzed as well as microbiome profiles in
relation to reproductive traits. The CHARGE-S WES
dataset is currently being analyzed for the contribution of
rare variants to ANM, while a very large meta-analyses of
age-at-menopause is underway involving many more HRC
imputed GWAS datasets as well as the UK Biobank dataset
of * 500,000 samples.
For additional EJE references see [405–415].
Pharmacoepidemiology
Objectives
Especially during the past 10 years, there has been a strong
increase in the number of automated healthcare databases
for pharmacoepidemiology. As most of these databases
have limitations because their composition is not only
healthcare-driven but may also differ between health
insurance systems, they are vulnerable to potential selec-
tion and information bias. This clarifies the need for
prospectively gathered and standardized information on
drugs and disease. In the Rotterdam Study, the role of
drugs is studied as determinant of diseases in middle-aged
and older community-dwelling individuals. This includes
studying efficacy and effectiveness of drugs, as well as
adverse reactions to drugs. As the drugs used in the Rot-
terdam Study are licensed and often on the market since
several years, research focuses on determinants which
modify the safety and effectiveness of widely used drugs
because these often have a great impact on healthcare. The
Rotterdam Study is a unique resource for pharmacoepi-
demiology because of its long follow-up since 1990,
complete coverage of more than five million dispensings of
prescription-only drugs via 7 automated community-based
pharmacies in the region, and repeated interview data for
studying drug adherence and ‘over-the-counter’ drugs. In
combination with the very rich medical and biological
information from repeated interviews and physical, labo-
ratory, imaging data, and genetic and epigenetic
determinants, it facilitates a type of pharmacoepidemio-
logic research which investigates biological-pharmacolog-
ical mechanisms of drug response.
Major findings
Below, we summarize findings over the most recent period.
Different research themes prevailed, centering around two
topics, i.e. studying important drug safety problems and
gene-drug interactions of established pharmacologic drug
effects. As for the first topic, an important problem for drug
licensing authrorities since several years is drug-induced
sudden cardiac death. In a recent analysis with data from
the Rotterdam Study, we demonstrated that the incidence
of sudden cardiac death during the period 1990–2010
declined [416]. Possibly, this is related to the increasing
attention for the treatment of cardiovascular morbidity
[secondary prevention] and of cardiovascular risk factors
such as hypertension and diabetes mellitus [primary pre-
vention]. One of the well-known risk factors for sudden
cardiac death is QTc-interval prolongation on echocardio-
grams [ECGs]. This QTc-interval prolongation is under the
influence of genetic variation [417]. An important gene—
ABCB1—encodes for the transport protein P-glycoprotein
which is abundant in the gut and blood brain barrier. Users
of digoxin with a certain variation of the ABCB1-gen had a
higher chance of sudden cardiac death [418]. There are
many drugs which are able to prolong the QTc-interval,
such as serotonin reuptake inhibitors [419]. These SSRI
antidepressants are considered to be safer than the tradi-
tional tricyclic antidepressants [TCA] when treating elderly
with depression but sometimes less effective. However,
SSRI are associated with an increased risk of cerebral
microbleeds [420]. On the other hand, we found that they
are associated with a lower risk of myocardial infarction
[421]. Although a large number of studies have been
conducted aiming to identify genetic variants associated
with antidepressant drug response in depression, only a few
variants have been repeatedly identified [422]. Depression
is the main indication for antidepressant treatment but
results from one of our studies confirmed that antidepres-
sants are also used for off-label indications, subthreshold
disorders and complex situations, which were all associated
with clinically-relevant depressive symptoms in the mid-
dle-aged and elderly population [423]. SSRI use was
associated with better subjective sleep, after adjustment for
depressive symptoms and concurrent psycholeptic drug
use. This suggests that, in clinical practice in the middle-
aged and elderly population, the sleep quality of some
persons may benefit from, continued, SSRI use [424]. The
stronger adverse effect of TCA on the QTc-interval proved
to be predominantly related to their more powerful anti-
cholinergic activity. This influence on the autonomic
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nervous system is associated with an increased heart rate.
The consequent decrease of the RR-interval mathemati-
cally leads to a prolongation of the QTc-interval according
to Bazett without changing the QT-interval itself. There-
fore, we demonstrated that the Fridericia-correction leads
to a more meaningful measure than the Bazett-corrected
one when calculating the QTc-interval from ECGs [425].
We conducted race/ethnic-specific genome-wide interac-
tion analyses of TCAs and resting RR and QT intervals in
cohorts of European, African, and Hispanic/Latino (n = 13
808; n = 147 TCA users) ancestry, adjusted for clinical
covariates. Among Europeans, TCA interactions with
variants in BRE and UBE2E2 were identified in relation to
RR intervals. Among Hispanic/Latinos, variants in
TGFBR3 modified the relation between TCAs and QT
intervals [426]. At variance with that which is suggested in
product labelling information, concurrent use of two or
more QTc-interval prolonging drugs did not further
lengthen the interval to a substantial extent [427]. How-
ever, It is clear that the association between QTc and
sudden cardiac death is not one-to-one and that other risk
factors are important. The role of a decreased serum level
of magnesium in cardiac arrhythmias is unclear at the
moment but we demonstrated that it was associated with an
increased risk of sudden cardiac death [428]. Although
hypomagnesemia is uncommon in a situation of normal
food intake, longterm use of proton pump inhibitors—for
instance indicated in elderly who are also chronic users of
NSAIDs—can cause this electrolyte disturbance [429].
We found that SSRI with a high receptor affinity had
relatively high serum levels of LDL cholesterol [430]. In
another analysis in the Rotterdam Study, we demonstrated
that use of SSRI was associated with a stronger weight
increase [431]. Also, SSRI decreased insulin secretion in
older adults and increased the risk of insulin dependence in
patents with type 2 diabetes [432]. In a methodological
study we tried to find support for the hypothesis that gen-
ome-wide association studies would be able to find genetic
determinants for response to SSRI, notably the genes
FSHR, HMGB4, PLCB1 and HTR2A [433].
Miscellaneous studies consisted, among others, of risk
factors in elderly for resistance to ciprofloxacin in com-
munity-acquired urinary tract infections due to E coli.
Ciprofloxacin resistance in community-acquired UTI was
associated with a high intake of pork and chicken and with
concomitant prescription of calcium supplements and
proton pump inhibitors [434]. In another study, a nested
case–control analysis was performed in which we found
that participants with a bacterial gastroenteritis were more
likely than controls to be current users of PPIs [435].
Furthermore, In a study in elderly from the Rotterdam
Study, B-proof, and LASA cohort, we were able to
demonstrate that two variants in cytochrome P450 2C9
modified the fall risk of ageing benzodiazepine users [436].
Future developments
More and more, pharmacoepidemiology in the Rotterdam
Study will concentrate on pharmacological-biological
mechanisms of a couple of commonly used benchmark
drugs with the help of genetic- and epigenetic techniques,
as well as proteomics and metabolomics. Several meta-
analyses were performed in recent years. First, in a large
international genome-wide association studie of drug-gene
interaction, no markers were found for the effect of anti-
hypertensives on cardiovascular disease [437]. One of
these antihypertensives, i.e. ACE-inhibitors, is associated
with angioedema or coughing which may lead to discon-
tinuation or switching to another antihypertensive. In a
second GWAs of 972 switchers from ACE-inhibitors, eight
SNPs within four genes reached the genome-wide associ-
ation study significance level in the meta-analysis: RNA
binding protein, Fox-1 homolog (Caenorhabditis elegans),
c-aminobutyric acid receptor subunit c-2, sarcoma (Src)
homology 2 (SH2) B adaptor protein 1 and membrane
bound O-acyltransferase domain containing 1 [438].
Third, in a large-scale GWAs of the effect of sulfony-
lurea hypoglycemics on QT, JT, and QRS intervals in 11
ethnically diverse cohorts that included 71 857 European,
African-American and Hispanic/Latino ancestry individu-
als eight novel pharmacogenomic loci met the threshold for
genome-wide significance. A pharmacokinetic variant in
CYP2C9 (rs1057910) that has been associated with sul-
fonylurea-related treatment effects and other adverse drug
reactions in previous studies was replicated [439]. Fourth,
we performed a large-scale meta-analysis across the
cohorts of the Metformin Genetics Consortium (MetGen).
Nine candidate polymorphisms in five transporter genes
(organic cation transporter [OCT]1, OCT2, multidrug and
toxin extrusion transporter [MATE]1, MATE2-K, and
OCTN1) were analyzed in up to 7968 individuals. None of
the variants showed a significant effect on metformin
response in the primary analysis, or in the exploratory
secondary analyses, when patients were stratified according
to possible confounding genotypes or prescribed daily dose
of metformin [440]. However, The C allele of rs8192675 in
the intron of SLC2A2, which encodes the facilitated glu-
cose transporter GLUT2, was associated with a 0.17%
greater metformin-induced reduction in hemoglobin A1c
(HbA1c) in 10,577 participants of European ancestry.
rs8192675 was the top cis expression quantitative trait
locus (cis-eQTL) for SLC2A2 in 1226 human liver sam-
ples, suggesting a key role for hepatic GLUT2 in regulation
of metformin action [441]. Fifth, we performed a meta-
analysis of genome-wide association studies (GWAS) to
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identify variants with an effect on statin-induced high
density lipoprotein cholesterol (HDL-C) changes. The 123
most promising signals were followed up in an independent
group of 10 951 statin-treated individuals, providing a total
sample size of 27,720 individuals. The only associations of
genome-wide significance were between minor alleles at
the CETP locus and greater HDL-C response to statin
treatment [442].
For additional EJE references see [435, 443–454].
Imaging studies
The Population Imaging Unit within the Rotterdam Study
aims to assess (quantitative) imaging biomarkers of disease
in a pre-symptomatic phase at the population level [455]
Advantages of imaging measures include that they mark
early disease, can be assessed reliably and reproducibly,
and are quantitative rather than qualitative which makes
them more powerful than most conventional outcome
measures such as clinical phenotypes.
The main imaging modalities that are currently being
applied in the Population Imaging Unit are multidetector
computed tomography (MDCT) and magnetic resonance
imaging (MRI). The imaging infrastructure has been
described extensively in the previous study design papers
[6, 19].
Important updates on our research since our last report
are the following:
Incidental findings on imaging
We previously indicated that assessment and management
of incidental findings is of great importance in large-scale
imaging studies like ours. Unfortunately, guidelines are
lacking and information on natural course is still scarce.
We have tried to close these gaps by describing an ethical
framework which can be used in designing studies
[456, 457], and we have reported the natural course and
clinical management of findings in our study since 2005
[458]
Imaging of age-related brain changes
and neurological diseases
An important focus in our work is on quantitative markers
that signify preclinical change, preferably in the earliest
state of disease. In this context, we have explored in recent
years how structural connectivity in the brain changes with
age [459,] and also how these changes affect cognition
[460]. Also, we showed that worse microstructural integrity
related to higher mortality [461]. Furthermore, we found
that future stroke is predicted not only by prevalent
vascular lesions (such as infarcts or white matter hyperin-
tensities) but also by subtle alterations in the microstructure
of normal-appearing white matter [254]. Inclusion of this
effect in risk prediction models produced a significant
advantage in stroke prediction compared with the existing
Framingham Stroke Risk Profile.
After introduction of resting-state functional MRI, we
have explored how (change in) brain structure drive brain
function, and found that white matter pathology can
decrease tract-specific functional connectivity, both in
direct and indirect connections [462]. These results provide
further evidence for the so-called ‘‘connectivity hypothe-
sis’’. We are currently extending this work by defining the
‘‘disconnectome’’ in the brain, and by studying how func-
tional brain connectivity changes with age and affects
cognitive functioning.
Despite increased understanding of microbleed pathol-
ogy, their clinical implications remained largely unknown.
We studied microbleeds as a determinant of stroke and
dementia and found that microbleeds associated with an
increased risk of recurrent and first-ever stroke, both
ischemic and hemorrhagic [463]. Our results confirm that
the increased risk is not confined to people with prior
strokes, and can be extrapolated to people from the general
population. Another finding was the correlation in
anatomical location between cerebral microbleeds and
intracerebral haemorrhage [463]. Finally, in longitudinal
studies we found that microbleed presence related to
decrease in cognitive functioning and an increased the risk
of dementia, including Alzheimer’s dementia [464]. Taken
together, our findings suggest that cerebral microbleeds
may represent an imaging marker of active vasculopathy,
which serves as a predictor of both ischemic and hemor-
rhagic brain lesions and neurodegeneration.
Imaging of atherosclerosis and cardiovascular
diseases
As described previously [6], we make use of both MDCT
and MRI to image atherosclerotic calcifications (in multi-
ple vessel beds), plaque burden and atherosclerotic plaque
composition (in the carotid). Important new reports
describe the determinants of overall plaque burden and
how plaque composition relates to a history of stroke
[465, 466]. In recent years, we have expanded our interest
in imaging markers of cardiovascular disease towards
epicardial fat [467, 468] and aortic valve calcification
[253, 469].
In a preliminary investigation, we have applied com-
putational fluid modelling to investigate the relation
between shear stress and vulnerable plaque components,
and found that higher shear stress related to intraplaque
haemorrhage [470]. We are currently expanding this study
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to measure shear stress in over 2000 carotid MRI scans
from our population. Using serial imaging, we were able to
describe determinants of change in plaque components
over time [471].
Future developments
As also mentioned above, focus has shifted in recent years
from purely structural imaging to also including functional
imaging data, by incorporating resting-state functional
MRI into the brain imaging protocol. Changes in the
intrinsic activity of resting-state networks are presumed to
represent alterations in functional brain connectivity and
may mark neurodegeneration in an early, presymptomatic
stage. We will further explore the value of functional
imaging as an early imaging marker for dementia, by itself
or in combination with other imaging markers and risk
factors.
Another development that has set in and will continue in
the coming years is that we do not regard the brain as a
stand-alone organ, but rather view it in the context of the
rest of the body and other diseases outside the brain. In the
past years, we have found abundant evidence that pathol-
ogy in the brain is linked to (sub)clinical pathology else-
where in the body [314, 315, 472–474], and we will
explore these interconnections further.
Finally, an emerging potential marker is Virchow–Robin
(VR) spaces, or enlarged perivascular spaces, spaces filled
with interstitial fluid that surround the blood vessels in the
brain and which can be dilated. Despite increasing litera-
ture on these dilated VR spaces, a major limitation of
current research is the lack of a robust and generalizable
rating method on MRI. After successful implementation of
a new rating method, we are currently investigating the
value of VR spaces in a large consortium of other popu-
lation-based studies [475] (www.uconsortium.org).
Besides ever-increasing advances in imaging hardware,
software and sequence design, major advances in the short
and long run are to be expected from (fully) automated
image analysis. Computer processing of images will enable
to make fully use of all information contained within the
image, introducing new imaging biomarkers. Besides, the
vast amount of imaging data that are acquired in popula-
tion-based studies like the Rotterdam Study renders visual
assessment or manual measurements virtually impossible,
strengthening the need for (fully) automated methods of
data extraction and analysis.
For additional EJE references see [457, 476].
Otorhinolaryngology
Objectives
Otolaryngological research in the Rotterdam Study focuses
on the frequency, etiology and consequences of hearing
loss. Age-related hearing loss is a common disorder that
deprives older people of key sensory input. It leads to
social withdrawal and is even been found to be indepen-
dently associated with poorer cognitive functioning and
incident dementia. Still, little is known about the mecha-
nisms that are responsible for developing hearing loss and
the way it affects general cognitive functions within the
elderly population. Determinants of interest are genetic
factors, cardiovascular disease, use of medication, endo-
crine diseases and neuro-epidemiological factors.
Methods
Hearing loss is assessed at both ears by performing pure-
tone audiometry in a sound proof room. Hearing thresholds
are determined with headphones at frequencies 0.25, 0.5, 1,
2, 4 and 8 kHz. To distinguish between cochlear and
middle-ear pathology, also bone-conduction thresholds are
measured at frequencies 0.5 and 4 kHz. Additionally,
speech perception in noise is tested at the better ear, using a
validated triplet digit test [477] with speech-shaped noise at
a fixed presentation level of 65 dB SPL. The ability to
understand speech in noise is a functional measure that
includes both sensory and central aspects of the auditory
system.
From a subset of the participants peripheral vestibular
function is assessed by The Head Impulse Test (HIT),
which measures the vestibule-ocular reflex (VOR) for a
number of sudden head movements initiated by the tester
[478]. Gain and delay are the main parameters that will be
used to quantify vestibular function. The main goal is to
analyze possible associations between cochlear and
vestibular dysfunction, as both sensory organs are con-
nected and use similar mechanisms.
The general interview contains ten questions related to
hearing and balance problems. In case of hearing-aid use,
the participant has to answer five additional questions of
the International Outcome Inventory of Hearing Aids (IOI-
HA) [479]. In case of frequent tinnitus, ten additional
questions of the Short Tinnitus Handicap Inventory (THI-
S) are added [480].
Major findings
As expected, we found a high prevalence of hearing loss in
population of the Rotterdam Study [481]. In the population
834 M. A. Ikram et al.
123
of 65 years and older, 30% had a hearing loss of 35 dB HL
of more. However, the difference in hearing between sexes
was considerably less than previously reported. This is
probably due to changing lifestyle and environmental cir-
cumstances. A general association study including relevant
determinants revealed that hearing loss was independently
associated with age, education, systolic blood pressure,
diabetes mellitus, BMI, smoking and alcohol consumption
[482]. Remarkably, different associations were found for
low- and high-frequency loss, as well as between men and
women, suggesting that different mechanisms are involved
in the etiology of age-related hearing loss. Furthermore, a
strong and consistent relation was found between hearing
loss and a decreased ability to understand speech in noise
[483], which confirms the substantial impact of hearing
loss on social interaction. To further analyse the possible
impact of hearing on general functioning, we studied the
relation of hearing loss with brain-related parameters. This
study revealed that hearing loss was independently asso-
ciated with a smaller brain volume [484], which was
mainly driven by a smaller white matter volume throughout
the brain in case of poorer hearing. Genetic susceptibility
to age-related hearing loss is another important topic that is
being analysed at the moment in a large meta-analysis of
the international CHARGE consortium.
For additional EJE references see [485–487].
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